Item 1. Financial Statements

524K characters. Original on sec.gov · Markdown

Item 1. Financial Statements

MetLife, Inc.

Interim Condensed Consolidated Balance Sheets

June 30, 2026 and December 31, 2025 (Unaudited)

(In millions, except share and per share data)


	June 30, 2026		December 31, 2025
Assets
Investments:
Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $224 and $249, respectively); and amortized cost: $347,781 and $337,201, respectively	$	322,183	$	315,931
Equity securities, at estimated fair value	932		858
Contractholder-directed equity securities and fair value option securities, at estimated fair value (includes $1,985 and $1,751, respectively, relating to variable interest entities)	14,809		13,959
Mortgage loans (net of allowance for credit loss of $1,358 and $1,193, respectively; includes $0 and $35, respectively, of mortgage loans held-for-sale)	82,856		84,593
Policy loans	8,226		8,547
Real estate and real estate joint ventures (includes $377 and $378, respectively, under the fair value option; $178 and $132, respectively, of real estate held-for-sale; $431 and $302, respectively, relating to variable interest entities)	13,065		13,440
Other limited partnership interests	14,801		14,917
Short-term investments, principally at estimated fair value	8,016		3,601
Other invested assets (includes $1,637 and $1,698, respectively, of leveraged and direct financing leases; $623 and $560, respectively, relating to variable interest entities)	17,675		16,332
Total investments	482,563		472,178
Cash and cash equivalents, principally at estimated fair value (includes $357 and $96, respectively, relating to variable interest entities)	19,301		22,032
Accrued investment income	3,774		3,719
Premiums, reinsurance and other receivables	50,635		49,059
Market risk benefits, at estimated fair value	490		458
Deferred policy acquisition costs and value of business acquired	21,571		21,107
Current income tax recoverable	426		660
Deferred income tax asset	3,167		2,585
Goodwill	9,536		9,613
Other assets	11,059		11,822
Separate account assets	156,850		151,933
Total assets	$	759,372	$	745,166
Liabilities, Mezzanine Equity and Equity
Liabilities
Future policy benefits	$	206,150	$	208,855
Policyholder account balances	245,458		236,857
Market risk benefits, at estimated fair value	2,235		2,406
Other policy-related balances	20,559		20,070
Policyholder dividends payable	349		356
Payables for collateral under securities loaned and other transactions	18,882		17,115
Short-term debt (includes $114 and $117, respectively, relating to variable interest entities)	460		355
Long-term debt (includes $69 and $28, respectively, relating to variable interest entities)	14,244		14,467
Collateral financing arrangement	286		352
Subordinated debt securities	5,144		4,155
Notes issued by collateralized financing entities (includes all amounts: under the fair value option; and relating to variable interest entities)	1,497		1,206
Deferred income tax liability	311		536
Other liabilities (includes $374 and $167, respectively, relating to variable interest entities)	58,986		57,582
Separate account liabilities	156,850		151,933
Total liabilities	731,411		716,245
Contingencies, Commitments and Guarantees (Note 18)
Mezzanine Equity
Redeemable noncontrolling interests	220		241
Equity
MetLife, Inc.’s stockholders’ equity:
Preferred stock, par value $0.01 per share; $2,905 aggregate liquidation preference	—		—
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,196,795,831 and 1,195,587,190 shares issued, respectively; 637,752,080 and 655,333,773 shares outstanding, respectively	12		12
Additional paid-in capital	32,933		32,858
Retained earnings	45,380		44,290
Treasury stock, at cost; 559,043,751 and 540,253,417 shares, respectively	(32,141)		(30,678)
Accumulated other comprehensive income (loss)	(18,743)		(18,084)
Total MetLife, Inc.’s stockholders’ equity	27,441		28,398
Noncontrolling interests	300		282
Total equity	27,741		28,680
Total liabilities, mezzanine equity and equity	$	759,372	$	745,166

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Three Months and Six Months Ended June 30, 2026 and 2025 (Unaudited)

(In millions, except per share data)


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Revenues
Premiums	$	11,435	$	10,810	$	23,555	$	22,533
Universal life and investment-type product policy fees	1,372		1,259		2,715		2,488
Net investment income	6,702		5,661		12,057		10,546
Other revenues	845		679		1,697		1,366
Net investment gains (losses)	(428)		(273)		(1,098)		(660)
Net derivative gains (losses)	(772)		(796)		(698)		(364)
Total revenues	19,154		17,340		38,228		35,909
Expenses
Policyholder benefits and claims	11,335		10,767		23,199		22,573
Policyholder liability remeasurement (gains) losses	18		5		5		(26)
Market risk benefit remeasurement (gains) losses	(270)		(277)		(150)		22
Interest credited to policyholder account balances	3,067		2,400		4,741		4,047
Policyholder dividends	125		146		249		290
Other expenses	3,844		3,319		7,642		6,669
Total expenses	18,119		16,360		35,686		33,575
Income (loss) before provision for income tax	1,035		980		2,542		2,334
Provision for income tax expense (benefit)	256		245		601		649
Net income (loss)	779		735		1,941		1,685
Less: Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests	43		6		20		11
Net income (loss) attributable to MetLife, Inc.	736		729		1,921		1,674
Less: Preferred stock dividends	31		31		76		97

Net income (loss) available to MetLife, Inc.’s common shareholders	$	705	$	698	$	1,845	$	1,577
Comprehensive income (loss)	$	1,251	$	1,125	$	1,294	$	4,085
Less: Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests, net of income tax	31		7		32		10
Comprehensive income (loss) attributable to MetLife, Inc.	$	1,220	$	1,118	$	1,262	$	4,075





Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
Basic	$	1.10	$	1.04	$	2.85	$	2.33
Diluted	$	1.09	$	1.03	$	2.83	$	2.32

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Equity

Six Months Ended June 30, 2026 and 2025 (Unaudited)

(In millions, except per share data)


	Preferred Stock		Common Stock		Additional Paid-in Capital		Retained Earnings		Treasury Stock at Cost		Accumulated Other Comprehensive Income (Loss)		Total MetLife, Inc.’s Stockholders’ Equity		Noncontrolling Interests		Total Equity
Balance at December 31, 2025	$	—	$	12	$	32,858	$	44,290	$	(30,678)	$	(18,084)	$	28,398	$	282	$	28,680
Treasury stock acquired in connection with share repurchases (includes $7 of excise tax)									(762)				(762)				(762)
Stock-based compensation					63								63				63
Dividends on preferred stock							(45)						(45)				(45)
Dividends on common stock (declared per share of $0.568)							(372)						(372)				(372)
Change in equity of noncontrolling interests													—		(12)		(12)
Net income (loss)							1,185						1,185		5		1,190
Other comprehensive income (loss), net of income tax											(1,143)		(1,143)		(4)		(1,147)
Balance at March 31, 2026	$	—	$	12	$	32,921	$	45,058	$	(31,440)	$	(19,227)	$	27,324	$	271	$	27,595
Treasury stock acquired in connection with share repurchase (includes $6 of excise tax)									(701)				(701)				(701)
Stock-based compensation					12								12				12
Dividends on preferred stock							(31)						(31)				(31)
Dividends on common stock (declared per share of $0.593 )							(383)						(383)				(383)
Change in equity of noncontrolling interests													—		(2)		(2)
Net income (loss)							736						736		32		768
Other comprehensive income (loss), net of income tax											484		484		(1)		483
Balance at June 30, 2026	$	—	$	12	$	32,933	$	45,380	$	(32,141)	$	(18,743)	$	27,441	$	300	$	27,741


	Preferred Stock		Common Stock		Additional Paid-in Capital		Retained Earnings		Treasury Stock at Cost		Accumulated Other Comprehensive Income (Loss)		Total MetLife, Inc.’s Stockholders’ Equity		Noncontrolling Interests		Total Equity
Balance at December 31, 2024	$	—	$	12	$	33,791	$	42,626	$	(27,798)	$	(21,186)	$	27,445	$	258	$	27,703
Cumulative effects of change in accounting principles for equity method investees at January 1, 2025											(1,074)		(1,074)				(1,074)
Treasury stock acquired in connection with share repurchases (includes $13 of excise tax)									(1,424)				(1,424)				(1,424)
Stock-based compensation					29								29				29
Dividends on preferred stock							(66)						(66)				(66)
Dividends on common stock (declared per share of $0.545)							(374)						(374)				(374)
Change in equity of noncontrolling interests													—		1		1
Net income (loss)							945						945		5		950
Other comprehensive income (loss), net of income tax											2,012		2,012		(2)		2,010
Balance at March 31, 2025	$	—	$	12	$	33,820	$	43,131	$	(29,222)	$	(20,248)	$	27,493	$	262	$	27,755
Treasury stock acquired in connection with share repurchases (includes $5 of excise tax)									(515)				(515)				(515)
Stock-based compensation					2								2				2
Dividends on preferred stock							(31)						(31)				(31)
Dividends on common stock (declared per share of $0.568)							(382)						(382)				(382)
Change in equity of noncontrolling interests													—		(27)		(27)
Net income (loss)							729						729		6		735
Other comprehensive income (loss), net of income tax											389		389		1		390
Balance at June 30, 2025	$	—	$	12	$	33,822	$	43,447	$	(29,737)	$	(19,859)	$	27,685	$	242	$	27,927

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Cash Flows

Six Months Ended June 30, 2026 and 2025 (Unaudited)

(In millions)


	Six Months Ended June 30,
	2026		2025
Net cash provided by (used in) operating activities	$	4,915	$	6,449
Cash flows from investing activities
Sales, maturities and repayments of:
Fixed maturity securities available-for-sale	40,933		27,503
Equity securities	82		54
Fair value option securities	154		—
Mortgage loans	8,241		6,421
Real estate and real estate joint ventures	635		72
Other limited partnership interests	682		504
Short-term investments	7,256		7,439
Purchases and originations of:
Fixed maturity securities available-for-sale	(50,384)		(35,502)
Equity securities	(173)		(48)
Fair value option securities	(256)		—
Mortgage loans	(7,109)		(4,214)
Real estate and real estate joint ventures	(499)		(387)
Other limited partnership interests	(1,047)		(650)
Short-term investments	(11,050)		(7,427)
Cash received in connection with freestanding derivatives	1,091		1,438
Cash paid in connection with freestanding derivatives	(2,743)		(1,959)

Net change in policy loans	269		(30)
Net change in other invested assets	(398)		557
Other, net	(10)		(74)
Net cash provided by (used in) investing activities	(14,326)		(6,303)
Cash flows from financing activities
Policyholder account balances - deposits	57,020		55,756
Policyholder account balances - withdrawals	(50,094)		(51,669)
Net change in payables for collateral under securities loaned and other transactions	1,824		(118)


Long-term debt issued	65		713
Long-term debt repaid	(217)		(558)
Collateral financing arrangement repaid	(66)		(38)
Subordinated debt securities issued	1,000		1,000
Derivatives with certain financing elements and other derivative-related transactions, net	(151)		(74)
Proceeds from mortgage loan secured financing	180		334
Repayments of mortgage loan secured financing	(836)		(672)
Proceeds from notes issued by collateralized financing entities	843		—
Repayments of notes issued by collateralized financing entities	(537)		—
Treasury stock acquired in connection with share repurchases	(1,477)		(1,921)



Dividends on preferred stock	(76)		(97)
Dividends on common stock	(755)		(756)
Other, net	52		(231)
Net cash provided by (used in) financing activities	6,775		1,669
Effect of change in foreign currency exchange rates on cash and cash equivalents balances	(95)		295
Change in cash and cash equivalents	(2,731)		2,110




Cash and cash equivalents, beginning of period	22,032		20,068
Cash and cash equivalents, end of period	$	19,301	$	22,178


Supplemental disclosures of cash flow information
Net cash paid (received) for:
Interest	$	531	$	507
Income tax	$	819	$	930
Non-cash transactions:
Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions	$	1,170	$	—
Real estate and real estate joint ventures acquired in satisfaction of debt	$	182	$	186


Other invested assets received in connection with the sale of other limited partnership interests	$	347	$	20

See accompanying notes to the interim condensed consolidated financial statements**.**

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies

Business

“MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. In the fourth quarter of 2025, MetLife executed a reorganization to align with its strategic initiative to accelerate growth in asset management. As part of this reorganization, the Company adjusted its segment structure. MetLife Investment Management, the Company’s institutional asset management business (“MIM”), which was previously reported in Corporate & Other, became a reportable segment. MetLife Holdings was removed as a reportable segment, and its business is now primarily reported in Corporate & Other. Additionally, certain products formerly reported in MetLife Holdings were moved to Group Benefits and Retirement and Income Solutions (“RIS”). These changes were applied retrospectively for all periods presented, did not have an impact on prior period consolidated net income (loss) or consolidated adjusted earnings, and are collectively referred to as the “Strategic Reorganization.” As a result of the Strategic Reorganization, MetLife is organized into the following six segments: Group Benefits; RIS; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MIM. In addition, the Company continues to report certain of its results of operations in Corporate & Other. See Note 2 for further information on the Company’s segments and Corporate & Other.

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.

The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2025 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2025 Annual Report.

Consolidation

The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions are eliminated.

The Company uses either the equity method of accounting or the fair value option (“FVO”) for its investments in joint ventures, including real estate joint ventures (“REJVs”) and other limited partnership interests (“OLPI”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period.

Recent Accounting Pronouncements

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following table provides a description of ASUs recently issued by the FASB and the impact of their future adoption on the Company’s consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued**)**

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Future Adoption of Accounting Pronouncements

ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of June 30, 2026 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below.


Standard	Description	Effective Date and Method of Adoption	Impact on Financial Statements
ASU 2025-08, Financial Instruments - Credit Losses (Topic 326): Purchased Loans	The key amendments include expanding the population of acquired financial assets that are accounted for using the gross-up approach by creating a new category of assets called purchased seasoned loans (“PSLs”), which will be accounted for using the gross-up approach. The day-1 expected credit losses on PSLs will be reflected as an adjustment to the amortized cost basis rather than an expense.	Effective for annual and interim periods beginning January 1, 2027, to be applied prospectively (with early adoption permitted).	The Company is evaluating the impact of the guidance on its consolidated financial statements.
ASU 2025-06, Intangibles—Goodwill and Other— Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software	The key amendments remove all references to prescriptive and sequential software development project stages and require that an entity capitalize software costs when both: (i) management has authorized and committed to funding the software project; and (ii) it is probable that the project will be completed and the software will be used to perform the function intended.	Effective for annual and interim periods beginning January 1, 2028, to be applied either prospectively, retrospectively, or using a modified transition approach (with early adoption permitted as of the beginning of an annual reporting period).	The Company is evaluating the impact of the guidance on its consolidated financial statements.
ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as amended by ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying The Effective Date	The key amendments require disclosures in the notes to financial statements around employee compensation costs, depreciation, intangible asset amortization and certain other costs and expenses. Information on selling expenses is also required.	Effective for annual periods beginning January 1, 2027, and interim periods beginning January 1, 2028, to be applied prospectively with an option for retrospective application (with early adoption permitted).	The Company is evaluating the impact of the guidance on its consolidated financial statements.

2. Segment Information

In the fourth quarter of 2025, MetLife completed the Strategic Reorganization. As a result, MetLife is organized into the following six segments: Group Benefits; RIS; Asia; Latin America; EMEA; and MIM. In addition, the Company continues to report certain of its results of operations in Corporate & Other. See Note 1. In conjunction with the Strategic Reorganization, effective January 1, 2025, the Company amended agreements between MIM and other MetLife entities to manage general account investments at current market rate fees.

Group Benefits

The Group Benefits segment, based in the United States (“U.S.”), offers a broad range of products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include term, variable and universal life insurance, dental, group and individual disability, accident & health insurance and vision.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

RIS

The RIS segment, based in the U.S., offers a broad range of life and annuity-based insurance and investment products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include stable value and pension risk transfer products, institutional income annuities, structured settlements, longevity reinsurance solutions, benefit funding solutions, funded reinsurance solutions, and capital markets investment products.

Asia

The Asia segment offers a broad range of products and services to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, accident & health insurance and retirement and savings.

Latin America

The Latin America segment offers a broad range of products to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance.

EMEA

The EMEA segment offers products to individuals, corporations, other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance.

MIM

MIM provides asset management and advisory services to institutional investors worldwide in public and private fixed income, real estate, equity, alternatives, multi-asset solutions and insurance solutions. MIM also manages investments for the Company’s general account.

Financial Measure and Segment Accounting Policies

Adjusted earnings is used by the Company’s chief operating decision maker, its Chief Executive Officer, to evaluate performance and allocate resources. Adjusted earnings and related measures based on adjusted earnings are also the measures by which senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and related measures based on adjusted earnings allow analysis of the Company’s performance relative to its business plan and facilitate comparisons to industry results.

Consistent with GAAP guidance for segment reporting, adjusted earnings is the Company’s GAAP measure of segment performance and is reported below. The Company believes the presentation of adjusted earnings enhances its investors’ understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business.

Adjusted earnings focuses on the Company’s primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, (iii) revenues and costs related to divested businesses, and (iv) other adjustments. Also, adjusted earnings excludes results of discontinued operations under GAAP.

Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefit (“MRB”) remeasurement gains (losses) and goodwill impairments. Further, net investment income is adjusted to exclude similar items relating to joint ventures accounted for under the equity method, and policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

Asymmetrical and non-economic accounting adjustments are made in calculating adjusted earnings:

Universal life and investment-type product policy fees exclude asymmetrical accounting associated with in-force reinsurance.
Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment.
Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.
Policyholder benefits and claims excludes (i) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (ii) asymmetrical accounting associated with in-force reinsurance, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
Policyholder liability remeasurement gains (losses) excludes asymmetrical accounting associated with in-force reinsurance.
Interest credited to policyholder account balances (“PABs”) excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.

“Divested businesses” are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.

Other adjustments are made in calculating adjusted earnings:

Beginning in the fourth quarter of 2025, net investment income excludes depreciation of wholly-owned real estate and REJVs.
Net investment income and interest credited to PABs exclude certain amounts related to contractholder-directed equity securities.
Net investment income and other expenses exclude Reinsurance activity (as defined below).
Net investment income and interest expense on debt exclude amounts related to collateralized financing entities (“CFEs”) that are consolidated VIEs.
Other revenues and other expenses exclude asset management distribution fees on funds that are passed through to distribution partners.
Other revenues include fee revenue on synthetic guaranteed interest contracts (“GICs”) accounted for as freestanding derivatives.
Other expenses exclude (i) amortization and impairment of asset management intangible assets, (ii) implementation of new insurance regulatory requirements and other costs, and (iii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
“Reinsurance activity” relates to amounts subject to ceded reinsurance arrangements with third parties and joint ventures, including (i) the related investment returns and expenses which are passed through to the reinsurers and (ii) the corresponding invested assets and cash and cash equivalents.

Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above is calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The Company’s segment accounting policies are the same as those used to prepare the Company’s interim condensed consolidated financial statements. In addition, segment accounting policies include the method of capital allocation described below.

Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company’s business.

The Company’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.

Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings.

Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Expenses are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing.

Corporate & Other

Corporate & Other contains various run-off and developing businesses. Also included in Corporate & Other are the excess capital, as well as certain charges and activities, not allocated to the segments (including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions and enterprise-wide strategic initiatives), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, and the elimination of intersegment amounts (which generally relate to asset management fees and loans bearing interest rates commensurate with related borrowings).

The run-off businesses principally consist of operations relating to products and businesses that the Company no longer actively markets in the U.S. and were reported in the Company’s former MetLife Holdings segment. These products include: (i) variable, universal and term life insurance, (ii) whole life insurance, (iii) fixed and variable annuities, as well as the related guarantees, (iv) in-force block of assumed variable annuity guarantees from a third party, and (v) long-term care insurance, which offers protection against the potentially high costs of long-term health care services.

The financial measure and accounting policies used to prepare the Company’s segment results are the same as those used to prepare results for Corporate & Other. See “— Financial Measure and Segment Accounting Policies.”

Set forth in the tables below is certain financial information with respect to the Company’s segments for the three months and six months ended June 30, 2026 and 2025.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)


Three Months Ended June 30, 2026	Group Benefits		RIS		Asia		Latin America		EMEA		MIM
	(In millions)
Revenues
Premiums	$	5,819	$	1,587	$	1,237	$	1,498	$	698	$	—
Universal life and investment-type product policy fees	242		113		441		416		98		—
Net investment income (1)	357		2,219		1,375		587		67		2
Other revenues	451		69		20		(15)		10		317

Expenses
Policyholder benefits and claims and policyholder dividends	5,053		2,466		1,030		1,471		335		—
Policyholder liability remeasurement (gains) losses	(2)		3		(15)		5		(5)		—
Interest credited to PABs	69		908		862		101		21		—
Other expenses:
Amortization of deferred policy acquisition costs (“DAC”), value of business acquired (“VOBA”) and negative VOBA	8		24		214		186		110		—
Interest expense on debt	2		2		—		4		—		1
Direct and allocated expenses	529		86		299		171		120		227
Other segment expenses (2)	574		36		93		197		159		15
Provision for income tax expense (benefit)	133		86		170		83		25		19
Adjusted earnings	$	503	$	377	$	420	$	268	$	108	$	57


Three Months Ended June 30, 2025	Group Benefits		RIS		Asia		Latin America		EMEA		MIM
	(In millions)
Revenues
Premiums	$	5,801	$	1,210	$	1,278	$	1,260	$	626	$	—
Universal life and investment-type product policy fees	240		102		399		371		84		—
Net investment income (1)	345		2,166		1,204		445		61		2
Other revenues	405		70		22		3		9		237

Expenses
Policyholder benefits and claims and policyholder dividends	5,161		2,045		1,051		1,216		309		—
Policyholder liability remeasurement (gains) losses	(4)		1		(12)		—		4		—
Interest credited to PABs	73		903		757		96		20		—
Other expenses:
Amortization of DAC, VOBA and negative VOBA	7		21		223		137		88		—
Interest expense on debt	1		4		—		4		—		—
Direct and allocated expenses	507		89		304		143		111		158
Other segment expenses (2)	538		25		91		166		120		9
Provision for income tax expense (benefit)	107		90		143		84		28		18
Adjusted earnings	$	401	$	370	$	346	$	233	$	100	$	54

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)


Six Months Ended June 30, 2026	Group Benefits		RIS		Asia		Latin America		EMEA		MIM
	(In millions)
Revenues
Premiums	$	11,667	$	3,799	$	2,531	$	2,983	$	1,387	$	—
Universal life and investment-type product policy fees	472		222		868		835		197		—
Net investment income (1)	709		4,471		2,836		996		134		7
Other revenues	912		138		37		(22)		19		631

Expenses
Policyholder benefits and claims and policyholder dividends	10,200		5,532		2,118		2,820		672		—
Policyholder liability remeasurement (gains) losses	(4)		(17)		(30)		5		(2)		—
Interest credited to PABs	139		1,791		1,695		186		42		—
Other expenses:
Amortization of DAC, VOBA and negative VOBA	20		47		425		359		207		—
Interest expense on debt	3		5		—		9		—		2
Direct and allocated expenses	1,069		179		597		329		242		469
Other segment expenses (2)	1,142		72		188		403		300		28
Provision for income tax expense (benefit)	249		193		372		184		58		35
Adjusted earnings	$	942	$	828	$	907	$	497	$	218	$	104


Six Months Ended June 30, 2025	Group Benefits		RIS		Asia		Latin America		EMEA		MIM
	(In millions)
Revenues
Premiums	$	11,564	$	3,494	$	2,538	$	2,424	$	1,208	$	—
Universal life and investment-type product policy fees	473		206		805		711		162		—
Net investment income (1)	698		4,356		2,408		853		119		3
Other revenues	839		139		37		12		17		455

Expenses
Policyholder benefits and claims and policyholder dividends	10,344		5,165		2,088		2,307		586		—
Policyholder liability remeasurement (gains) losses	(22)		(14)		(23)		(3)		4		—
Interest credited to PABs	145		1,786		1,468		194		37		—
Other expenses:
Amortization of DAC, VOBA and negative VOBA	13		40		439		266		182		—
Interest expense on debt	2		7		—		8		—		—
Direct and allocated expenses	1,036		187		610		278		220		331
Other segment expenses (2)	1,080		59		183		342		240		18
Provision for income tax expense (benefit)	205		189		305		156		54		27
Adjusted earnings	$	771	$	776	$	718	$	452	$	183	$	82

(1)The percentage of net investment income from equity method invested assets by segment was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Group Benefits	(1)	%	—	%	—	%	—	%
RIS	4	%	4	%	6	%	5	%
Asia	12	%	10	%	15	%	10	%
Latin America	1	%	—	%	1	%	—	%
EMEA	1	%	—	%	1	%	—	%

(2)Includes pension, postretirement and postemployment benefit costs; premium taxes, other taxes, and licenses & fees; and commissions and other variable expenses. This line item is net of capitalization of DAC.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The Company does not report total assets by segment, as this metric is not used to allocate resources or evaluate segment performance.

The following table presents the reconciliation of certain financial measures used in calculating segment results to those used in calculating consolidated Company results:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
	(In millions)
Total segment adjusted earnings	$	1,733	$	1,504	$	3,496	$	2,982
Corporate & Other	(129)		(111)		(261)		(174)
Total consolidated adjusted earnings	1,604		1,393		3,235		2,808
Net investment gains (losses)	(428)		(273)		(1,098)		(660)
Net derivative gains (losses)	(772)		(796)		(698)		(364)
MRB remeasurement gains (losses)	270		277		150		(22)
Investment hedge adjustments	(170)		(102)		(254)		(205)
Depreciation of wholly-owned real estate and REJVs	(54)				(115)
Other	95		41		317		(90)
Provision for income tax (expense) benefit	234		195		404		218
Net income (loss)	$	779	$	735	$	1,941	$	1,685

Segment revenues:
Group Benefits	$	6,869	$	6,791	$	13,760	$	13,574
RIS	3,988		3,548		8,630		8,195
Asia	3,073		2,903		6,272		5,788
Latin America	2,486		2,079		4,792		4,000
EMEA	873		780		1,737		1,506
MIM (1)	319		239		638		458
Total segment revenues	17,608		16,340		35,829		33,521
Net investment gains (losses)	(428)		(273)		(1,098)		(660)
Net derivative gains (losses)	(772)		(796)		(698)		(364)
Investment hedge adjustments	(170)		(102)		(254)		(205)
Unit-linked investment income	998		498		680		271
Reinsurance activity	331		47		632		90
Corporate & Other revenue	1,467		1,581		2,928		3,227
Other	120		45		209		29
Total consolidated revenues	$	19,154	$	17,340	$	38,228	$	35,909

(1)Includes intersegment asset management fees of $133 million and $264 million for the three months and six months ended June 30, 2026, respectively, and $130 million and $259 million for the three months and six months ended June 30, 2025, respectively, earned in connection with management of general account investments of the Company.

3. Acquisitions and Dispositions

Acquisition of PineBridge Investments

In the fourth quarter of 2025, the Company completed the acquisition of PineBridge Investments, which is reported in the MIM segment, for the preliminary purchase consideration of $885 million. The purchase consideration and the purchase price allocation are preliminary and are subject to adjustment during the measurement period, which is up to one year from the acquisition date. See Note 3 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for further information on the acquisition.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Acquisitions and Dispositions (continued)

Pending Disposition of MetLife Ukraine

In the second quarter of 2026, the Company entered into a definitive agreement to sell its wholly-owned subsidiary, PJSC MetLife (“MetLife Ukraine”), which is reported in the EMEA segment. In connection with the anticipated disposal, an impairment loss of $65 million, net of income tax, was recorded for the three months and six months ended June 30, 2026, and is reflected in net investment gains (losses). The transaction is expected to close in 2027 and is subject to regulatory approvals and satisfaction of other closing conditions.

4. Future Policy Benefits

The Company establishes liabilities for amounts payable under insurance policies. These liabilities are comprised of traditional and limited-payment contracts and associated deferred profit liability (“DPL”), additional insurance liabilities, participating life and short-duration contracts.

The Company’s future policy benefits (“FPBs”) on the interim condensed consolidated balance sheets were as follows at:


	June 30, 2026		December 31, 2025
	(In millions)
Traditional and Limited-Payment Contracts:
RIS - Annuities	$	78,936	$	79,523
Asia:
Whole and term life & endowments	8,565		10,140
Accident & health	6,822		7,913
Latin America - Fixed annuities	12,608		12,336
Corporate & Other - Long-term care	15,345		15,224
Deferred Profit Liabilities:
RIS - Annuities	3,859		3,855
Asia:
Whole and term life & endowments	948		919
Accident & health	992		993
Latin America - Fixed annuities	555		562
Additional Insurance Liabilities:
Asia:
Variable life	1,025		1,074
Universal and variable universal life	318		330
Corporate & Other - Universal and variable universal life	2,766		2,713
Corporate & Other - Participating life	46,738		47,359
Other long-duration (1)	11,300		11,148
Short-duration and other	15,373		14,766
Total	$	206,150	$	208,855

(1)This balance represents liabilities for various smaller product lines across multiple segments, as well as Corporate & Other.

Rollforwards — Traditional and Limited-Payment Contracts

The following information about the direct and assumed liability for FPBs includes disaggregated rollforwards of expected future net premiums and expected future benefits. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers, except with respect to ending net liability for FPB balances where applicable.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

RIS — Annuities

The RIS segment’s annuity products include pension risk transfers (including assumed pension risk transfers from the United Kingdom (“U.K.”)), certain structured settlements and certain institutional income annuities, which are mainly single premium spread-based products. The Company reinsures portions of certain pension risk transfers and structured settlements on a modified coinsurance basis. Information regarding these products was as follows:


	Six Months Ended June 30,
	2026			2025
	(Dollars in millions)
Present Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet date	$	—		$	—

Balance, beginning of period, at original discount rate	$	—		$	—

Effect of actual variances from expected experience (1)	(4)			(39)
Adjusted balance	(4)			(39)
Issuances	2,169			2,769
Net premiums collected	(2,165)			(2,730)
Ending balance at original discount rate	—			—
Balance, end of period, at current discount rate at balance sheet date	$	—		$	—

Present Value of Expected FPBs
Balance, beginning of period, at current discount rate at balance sheet date	$	79,842		$	66,621

Balance, beginning of period, at original discount rate	$	81,498		$	69,643

Effect of actual variances from expected experience (1)	(30)			(100)
Adjusted balance	81,468			69,543
Issuances	2,187			2,797
Interest accrual	1,943			1,676
Benefit payments	(3,851)			(3,288)
Effect of foreign currency translation	(19)			27
Ending balance at original discount rate	81,728			70,755
Effect of changes in discount rate assumptions	(2,434)			(2,280)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	(1)			—
Balance, end of period, at current discount rate at balance sheet date	79,293			68,475

Cumulative amount of fair value hedging adjustments	(357)			(282)
Net liability for FPBs	78,936			68,193
Less: Reinsurance recoverables	12,104			2,207
Net liability for FPBs, net of reinsurance	$	66,832		$	65,986

Undiscounted - Expected future benefit payments	$	146,583		$	128,551
Discounted - Expected future benefit payments (at current discount rate at balance sheet date)	$	79,293		$	68,475
Weighted-average duration of the liability	8 years			8 years
Weighted-average interest accretion (original locked-in) rate	4.9		%	4.9		%
Weighted-average current discount rate at balance sheet date	5.6		%	5.5		%

(1)For the six months ended June 30, 2025, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $46 million.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

Asia

Whole and Term Life & Endowments

The Asia segment’s whole and term life & endowment products in Japan and Korea offer various life insurance coverages to customers. Information regarding these products was as follows:


	Six Months Ended June 30,
		2026			2025
		(Dollars in millions)
Present Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet date		$	3,910		$	4,023

Balance, beginning of period, at original discount rate		$	4,337		$	4,286

Effect of actual variances from expected experience		(32)			(44)
Adjusted balance		4,305			4,242
Issuances		346			290
Interest accrual		46			39
Net premiums collected		(332)			(313)
Effect of foreign currency translation		(148)			340
Ending balance at original discount rate		4,217			4,598
Effect of changes in discount rate assumptions		(528)			(332)
Effect of foreign currency translation on the effect of changes in discount rate assumptions		17			(25)
Balance, end of period, at current discount rate at balance sheet date		$	3,706		$	4,241

Present Value of Expected FPBs
Balance, beginning of period, at current discount rate at balance sheet date		$	14,050		$	15,190

Balance, beginning of period, at original discount rate		$	15,358		$	15,252

Effect of actual variances from expected experience		(12)			(43)
Adjusted balance		15,346			15,209
Issuances		346			290
Interest accrual		195			188
Benefit payments		(504)			(482)
Effect of foreign currency translation		(637)			1,286
Ending balance at original discount rate		14,746			16,491
Effect of changes in discount rate assumptions		(2,510)			(433)
Effect of foreign currency translation on the effect of changes in discount rate assumptions		32			27
Balance, end of period, at current discount rate at balance sheet date		12,268			16,085

Cumulative impact of flooring the future policyholder benefits reserve		3			—
Net liability for FPBs		8,565			11,844
Less: Amount due to reinsurer		(2)			(2)
Net liability for FPBs, net of reinsurance		$	8,567		$	11,846

Undiscounted:
Expected future gross premiums		$	9,042		$	9,474
Expected future benefit payments		$	25,791		$	27,843
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums		$	7,096		$	7,837
Expected future benefit payments		$	12,268		$	16,085
Weighted-average duration of the liability		15 years			17 years
Weighted-average interest accretion (original locked-in) rate		2.8		%	2.6		%
Weighted-average current discount rate at balance sheet date		4.5		%	3.0		%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

Accident & Health

The Asia segment’s accident & health products in Japan and Korea offer various hospitalization, cancer, critical illness, disability, income protection and personal accident coverage. Information regarding these products was as follows:


	Six Months Ended June 30,
	2026			2025
	(Dollars in millions)
Present Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet date	$	15,389		$	17,203

Balance, beginning of period, at original discount rate	$	18,243		$	18,820

Effect of actual variances from expected experience	(73)			(200)
Adjusted balance	18,170			18,620
Issuances	429			636
Interest accrual	106			113
Net premiums collected	(864)			(939)
Effect of foreign currency translation and other - net	(677)			1,836
Ending balance at original discount rate	17,164			20,266
Effect of changes in discount rate assumptions	(3,453)			(2,204)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	117			(161)
Balance, end of period, at current discount rate at balance sheet date	$	13,828		$	17,901

Present Value of Expected FPBs
Balance, beginning of period, at current discount rate at balance sheet date	$	23,153		$	26,565

Balance, beginning of period, at original discount rate	$	32,942		$	32,838

Effect of actual variances from expected experience	(77)			(208)
Adjusted balance	32,865			32,630
Issuances	429			635
Interest accrual	229			239
Benefit payments	(636)			(647)
Effect of foreign currency translation and other - net	(1,282)			3,064
Ending balance at original discount rate	31,605			35,921
Effect of changes in discount rate assumptions	(11,531)			(8,209)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	395			(572)
Balance, end of period, at current discount rate at balance sheet date	20,469			27,140

Cumulative impact of flooring the future policyholder benefits reserve	181			156
Net liability for FPBs	6,822			9,395
Less: Reinsurance recoverables	96			132
Net liability for FPBs, net of reinsurance	$	6,726		$	9,263

Undiscounted:
Expected future gross premiums	$	34,799		$	40,090
Expected future benefit payments	$	41,866		$	47,275
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums	$	24,022		$	30,717
Expected future benefit payments	$	20,469		$	27,140
Weighted-average duration of the liability	17 years			21 years
Weighted-average interest accretion (original locked-in) rate	1.7		%	1.7		%
Weighted-average current discount rate at balance sheet date	4.5		%	3.2		%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

Latin America — Fixed Annuities

The Latin America segment’s fixed annuity products in Chile and Mexico include fixed income annuities that provide for asset distribution needs. Information regarding these products was as follows:


	Six Months Ended June 30,
	2026			2025
	(Dollars in millions)
Present Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet date	$	—		$	—

Balance, beginning of period, at original discount rate	$	—		$	—

Effect of actual variances from expected experience	—			—
Adjusted balance	—			—
Issuances	879			740
Interest accrual	2			2
Net premiums collected	(881)			(742)
Ending balance at original discount rate	—			—
Balance, end of period, at current discount rate at balance sheet date	$	—		$	—

Present Value of Expected FPBs
Balance, beginning of period, at current discount rate at balance sheet date	$	12,336		$	9,600

Balance, beginning of period, at original discount rate	$	11,588		$	9,133

Effect of actual variances from expected experience	4			(1)
Adjusted balance	11,592			9,132
Issuances	894			778
Interest accrual	214			181
Benefit payments	(483)			(389)
Inflation adjustment	328			216
Effect of foreign currency translation	(270)			621
Ending balance at original discount rate	12,275			10,539
Effect of changes in discount rate assumptions	335			397
Effect of foreign currency translation on the effect of changes in discount rate assumptions	(2)			28
Balance, end of period, at current discount rate at balance sheet date	12,608			10,964

Net liability for FPBs	$	12,608		$	10,964

Undiscounted - Expected future benefit payments	$	18,052		$	15,671
Discounted - Expected future benefit payments (at current discount rate at balance sheet date)	$	12,608		$	10,964
Weighted-average duration of the liability	10 years			10 years
Weighted-average interest accretion (original locked-in) rate	3.6		%	3.7		%
Weighted-average current discount rate at balance sheet date	3.2		%	3.1		%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

Corporate & Other — Long-term Care

Corporate & Other’s long-term care products offer protection against potentially high costs of long-term health care services. Information regarding these products was as follows:


	Six Months Ended June 30,
	2026			2025
	(Dollars in millions)
Present Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet date	$	5,548		$	5,475

Balance, beginning of period, at original discount rate	$	5,515		$	5,568

Effect of actual variances from expected experience	57			(3)
Adjusted balance	5,572			5,565
Interest accrual	141			141
Net premiums collected	(288)			(280)
Ending balance at original discount rate	5,425			5,426
Effect of changes in discount rate assumptions	(42)			(6)
Balance, end of period, at current discount rate at balance sheet date	$	5,383		$	5,420

Present Value of Expected FPBs
Balance, beginning of period, at current discount rate at balance sheet date	$	20,772		$	20,012

Balance, beginning of period, at original discount rate	$	21,490		$	21,024

Effect of actual variances from expected experience	107			26
Adjusted balance	21,597			21,050
Interest accrual	566			553
Benefit payments	(498)			(452)
Ending balance at original discount rate	21,665			21,151
Effect of changes in discount rate assumptions	(937)			(928)
Balance, end of period, at current discount rate at balance sheet date	20,728			20,223

Net liability for FPBs	$	15,345		$	14,803

Undiscounted:
Expected future gross premiums	$	10,075		$	10,269
Expected future benefit payments	$	44,361		$	44,566
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums	$	6,745		$	6,870
Expected future benefit payments	$	20,728		$	20,223
Weighted-average duration of the liability	13 years			13 years
Weighted-average interest accretion (original locked-in) rate	5.4		%	5.4		%
Weighted-average current discount rate at balance sheet date	5.8		%	5.8		%

Rollforwards — Additional Insurance Liabilities

The Company establishes additional insurance liabilities for annuitization, death or other insurance benefits for variable life, universal life, and variable universal life contract features whereby the Company guarantees to the contractholder either a secondary guarantee or a guaranteed paid-up benefit. The policy can remain in force, even if the base policy account value is zero, as long as contractual secondary guarantee requirements have been met.

The following information about the direct liability for additional insurance liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in these rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

Asia — Variable Life and Universal and Variable Universal Life

The Asia segment’s variable life and universal and variable universal life products in Japan offer a contract feature whereby the Company guarantees to the contractholder a secondary guarantee. Information regarding these additional insurance liabilities was as follows:


	Six Months Ended June 30,
	2026			2025			2026			2025
	Variable Life						Universal and Variable Universal Life
	(Dollars in millions)
Balance, beginning of period	$	1,074		$	1,108		$	330		$	355
Less: Accumulated other comprehensive income (loss) (“AOCI”) adjustment	—			—			32			10
Balance, beginning of period, before AOCI adjustment	1,074			1,108			298			345

Effect of actual variances from expected experience	(4)			(6)			(2)			(4)
Adjusted balance	1,070			1,102			296			341
Assessments accrual	(2)			(2)			(4)			—
Interest accrual	8			9			2			3
Excess benefits paid	(13)			(19)			—			—
Effect of foreign currency translation and other, net	(38)			98			(11)			31
Balance, end of period, before AOCI adjustment	1,025			1,188			283			375
Add: AOCI adjustment	—			—			35			11
Balance, end of period	$	1,025		$	1,188		$	318		$	386

Weighted-average duration of the liability	16 years			16 years			41 years			42 years
Weighted-average interest accretion rate	1.5		%	1.5		%	1.5		%	1.5		%

Corporate & Other — Universal and Variable Universal Life

Corporate & Other’s universal and variable universal life products provide a contract feature whereby the Company guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding these additional insurance liabilities was as follows:


	Six Months Ended June 30,
	2026			2025
	Universal and Variable Universal Life
	(Dollars in millions)
Balance, beginning of period	$	2,713		$	2,496
Less: AOCI adjustment	(13)			(17)
Balance, beginning of period, before AOCI adjustment	2,726			2,513

Effect of actual variances from expected experience	31			18
Adjusted balance	2,757			2,531
Assessments accrual	55			54
Interest accrual	74			68
Excess benefits paid	(107)			(71)
Balance, end of period, before AOCI adjustment	2,779			2,582
Add: AOCI adjustment	(13)			(15)
Balance, end of period	2,766			2,567
Less: Reinsurance recoverables	2,408			2,230
Balance, end of period, net of reinsurance	$	358		$	337

Weighted-average duration of the liability	14 years			15 years
Weighted-average interest accretion rate	5.5		%	5.5		%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

The Company’s gross premiums or assessments and interest expense recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding Corporate & Other’s participating life contracts, were as follows:


		Six Months Ended June 30,
		2026				2025
		Gross Premiums or Assessments (1)		Interest Expense (2)		Gross Premiums or Assessments (1)		Interest Expense (2)
	(In millions)
Traditional and Limited-Payment Contracts:
RIS - Annuities		$	2,264	$	1,943	$	2,799	$	1,676
Asia:
Whole and term life & endowments		653		149		600		149
Accident & health		1,455		123		1,561		126
Latin America - Fixed annuities		881		212		742		179
Corporate & Other - Long-term care		363		425		359		412
Deferred Profit Liabilities:
RIS - Annuities		N/A		93		N/A		91
Asia:
Whole and term life & endowments		N/A		25		N/A		21
Accident & health		N/A		12		N/A		11
Latin America - Fixed annuities		N/A		11		N/A		10
Additional Insurance Liabilities:
Asia:
Variable life		112		8		72		9
Universal and variable universal life		31		2		1		3
Corporate & Other - Universal and variable universal life		295		74		317		68
Other long-duration		3,173		253		2,476		243
Total		$	9,227	$	3,330	$	8,927	$	2,998

(1)Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income.

(2)Interest expense is included in policyholder benefits and claims.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Future Policy Benefits (continued)

Liabilities for Unpaid Claims and Claim Expenses

Rollforward of Claims and Claim Adjustment Expenses

Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:


	Six Months Ended June 30,
	2026		2025
	(In millions)
Balance, beginning of period	$	17,130	$	16,118
Less: Reinsurance recoverables	2,906		2,790
Net balance, beginning of period	14,224		13,328
Incurred related to:
Current period	14,609		14,590
Prior periods (1)	109		138
Total incurred	14,718		14,728
Paid related to:
Current period	(9,214)		(9,127)
Prior periods	(5,069)		(4,763)
Total paid	(14,283)		(13,890)


Net balance, end of period	14,659		14,166
Add: Reinsurance recoverables	3,094		3,022
Balance, end of period (included in FPBs and other policy-related balances)	$	17,753	$	17,188

(1)For the six months ended June 30, 2026 and 2025, incurred claims and claim adjustment expenses associated with prior periods increased due to events incurred in prior periods but reported in the respective current period.

5. Policyholder Account Balances

The Company establishes liabilities for PABs, which are generally equal to the account value, and which include accrued interest credited, but exclude the impact of any applicable charge that may be incurred upon surrender.

The Company’s PABs on the interim condensed consolidated balance sheets were as follows at:


	June 30, 2026		December 31, 2025
	(In millions)
Group Benefits - Life	$	11,109	$	11,005
RIS:
Capital markets investment products and stable value GICs	68,616		65,592
Annuities and risk solutions	29,122		26,406
Asia:
Universal and variable universal life	55,090		54,374
Fixed annuities	45,099		43,188
Corporate & Other:
Annuities	6,039		6,383
Life and other	6,982		7,109
Other	23,401		22,800
Total	$	245,458	$	236,857

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

Rollforwards

The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance.

Group Benefits

Life

The Group Benefits segment’s life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account portion of variable life insurance products. Information regarding this liability was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	11,005	$	7,632
Transfer (1)	—		3,773
Deposits	2,465		2,000
Policy charges	(333)		(336)
Surrenders and withdrawals	(2,158)		(1,993)
Benefit payments	(6)		(5)
Net transfers from (to) separate accounts	—		1
Interest credited	136		141

Balance, end of period	$	11,109	$	11,213

Weighted-average annual crediting rate	2.5 %		2.5 %

At period end:
Cash surrender value	$	11,037	$	11,149
Net amount at risk, excluding offsets from reinsurance:
In the event of death	$	269,231	$	267,754

(1)A product previously reported within the former MetLife Holdings segment was moved to the Group Benefits segment as part of the Strategic Reorganization. Accordingly, the reported balances for the six months ended June 30, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

The Group Benefits segment’s life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	515	$	93	$	732	$	4,451	$	5,791
Equal to or greater than 2% but less than 4%	4,373		95		85		—		4,553
Equal to or greater than 4%	651		24		—		59		734
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		31
Total	$	5,539	$	212	$	817	$	4,510	$	11,109

June 30, 2025
Equal to or greater than 0% but less than 2%	$	479	$	76	$	792	$	4,159	$	5,506
Equal to or greater than 2% but less than 4%	4,747		101		60		—		4,908
Equal to or greater than 4%	687		26		3		50		766
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		33
Total	$	5,913	$	203	$	855	$	4,209	$	11,213

RIS

Capital Markets Investment Products and Stable Value GICs

The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	65,592	$	63,715
Deposits	41,653		42,621

Surrenders and withdrawals	(39,388)		(42,716)


Interest credited	1,205		1,202
Effect of foreign currency translation and other, net	(446)		1,735
Balance, end of period	$	68,616	$	66,557

Weighted-average annual crediting rate	3.7 %		3.8 %
Cash surrender value at period end	$	1,737	$	1,268

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	—	$	—	$	—	$	2,485	$	2,485


Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		66,131
Total	$	—	$	—	$	—	$	2,485	$	68,616

June 30, 2025
Equal to or greater than 0% but less than 2%	$	—	$	—	$	—	$	2,591	$	2,591


Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		63,966
Total	$	—	$	—	$	—	$	2,591	$	66,557

Annuities and Risk Solutions

The RIS segment’s annuity and risk solutions PABs include certain structured settlements and institutional income annuities, group and individual fixed deferred annuities, the fixed account portion of group variable deferred annuities, registered index-linked annuities and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	26,406	$	20,699
Transfer (1)	—		3,109
Deposits	3,464		2,012
Policy charges	(102)		(99)
Surrenders and withdrawals	(895)		(514)
Benefit payments	(633)		(564)
Net transfers from (to) separate accounts	1		32
Interest credited	560		490
Other	321		18
Balance, end of period	$	29,122	$	25,183

Weighted-average annual crediting rate	4.1 %		4.1 %

At period end:
Cash surrender value	$	15,912	$	13,162
Net amount at risk, excluding offsets from reinsurance:
In the event of death	$	47,144	$	46,711
At annuitization or exercise of other living benefits	$	18	$	12

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the six months ended June 30, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	—	$	—	$	8	$	4,474	$	4,482
Equal to or greater than 2% but less than 4%	459		2,114		538		1,710		4,821
Equal to or greater than 4%	4,185		—		290		6		4,481
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		15,338
Total	$	4,644	$	2,114	$	836	$	6,190	$	29,122

June 30, 2025
Equal to or greater than 0% but less than 2%	$	—	$	—	$	8	$	2,817	$	2,825
Equal to or greater than 2% but less than 4%	370		2,446		601		1,224		4,641
Equal to or greater than 4%	4,379		11		423		6		4,819
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		12,898
Total	$	4,749	$	2,457	$	1,032	$	4,047	$	25,183

Asia

Universal and Variable Universal Life

The Asia segment’s universal and variable universal life PABs in Japan primarily include interest sensitive whole life products. Information regarding this liability was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	54,374	$	50,801
Deposits	2,878		2,817
Policy charges	(457)		(482)
Surrenders and withdrawals	(1,877)		(1,336)
Benefit payments	(266)		(292)

Interest credited	886		783
Effect of foreign currency translation and other, net	(448)		1,273
Balance, end of period	$	55,090	$	53,564

Weighted-average annual crediting rate	3.3 %		3.1 %

At period end:
Cash surrender value	$	48,263	$	46,520
Net amount at risk, excluding offsets from reinsurance:
In the event of death	$	78,300	$	86,369

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

The Asia segment’s universal and variable universal life account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	9,412	$	11	$	271	$	2,151	$	11,845
Equal to or greater than 2% but less than 4%	6,765		15,878		4,749		12,240		39,632
Equal to or greater than 4%	223		—		—		—		223
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		3,390
Total	$	16,400	$	15,889	$	5,020	$	14,391	$	55,090

June 30, 2025
Equal to or greater than 0% but less than 2%	$	10,673	$	24	$	245	$	1,813	$	12,755
Equal to or greater than 2% but less than 4%	7,575		15,942		5,047		11,063		39,627
Equal to or greater than 4%	232		—		—		—		232
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		950
Total	$	18,480	$	15,966	$	5,292	$	12,876	$	53,564

Fixed Annuities

Information regarding the Asia segment’s fixed annuity PAB liability in Japan was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	43,188	$	38,421
Deposits	3,293		3,738
Policy charges	(8)		(2)
Surrenders and withdrawals	(1,310)		(828)
Benefit payments	(974)		(936)

Interest credited	730		601
Effect of foreign currency translation and other, net	180		425
Balance, end of period	$	45,099	$	41,419

Weighted-average annual crediting rate	3.4 %		3.1 %

At period end:
Cash surrender value	$	40,312	$	36,270
Net amount at risk, excluding offsets from reinsurance:
In the event of death	$	4	$	1

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

The Asia segment’s fixed annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	258	$	317	$	3,639	$	39,872	$	44,086
Equal to or greater than 2% but less than 4%	—		4		—		—		4

Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		1,009
Total	$	258	$	321	$	3,639	$	39,872	$	45,099

June 30, 2025
Equal to or greater than 0% but less than 2%	$	293	$	457	$	4,443	$	35,016	$	40,209
Equal to or greater than 2% but less than 4%	—		4		—		—		4

Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		1,206
Total	$	293	$	461	$	4,443	$	35,016	$	41,419

Corporate & Other

Annuities

Corporate & Other’s annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	6,383	$	10,142
Transfer (1)	—		(3,109)
Deposits	59		57
Policy charges	(4)		(5)
Surrenders and withdrawals	(423)		(462)
Benefit payments	(135)		(168)
Net transfers from (to) separate accounts	58		70
Interest credited	99		107
Other	2		1
Balance, end of period	$	6,039	$	6,633

Weighted-average annual crediting rate	3.3 %		3.2 %

At period end:
Cash surrender value	$	5,551	$	6,094
Net amount at risk, excluding offsets from reinsurance (2):
In the event of death	$	2,114	$	2,413
At annuitization or exercise of other living benefits	$	732	$	720

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

(2)Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs, which are disclosed in “Corporate & Other – Annuities” in Note 6.

Corporate & Other’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	39	$	10	$	461	$	164	$	674
Equal to or greater than 2% but less than 4%	2,485		1,463		223		47		4,218
Equal to or greater than 4%	640		170		4		—		814
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		333
Total	$	3,164	$	1,643	$	688	$	211	$	6,039

June 30, 2025
Equal to or greater than 0% but less than 2%	$	29	$	25	$	492	$	66	$	612
Equal to or greater than 2% but less than 4%	2,553		1,825		323		81		4,782
Equal to or greater than 4%	490		380		7		—		877
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		362
Total	$	3,072	$	2,230	$	822	$	147	$	6,633

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

Life and Other

Corporate & Other’s life and other PABs include universal life products, the fixed account portion of variable life insurance products and funding agreements. Information regarding this liability was as follows:


	Six Months Ended June 30,
	2026		2025
	(Dollars in millions)
Balance, beginning of period	$	7,109	$	11,132
Transfer (1)	—		(3,773)
Deposits	269		256
Policy charges	(322)		(336)
Surrenders and withdrawals	(157)		(132)
Benefit payments	(75)		(79)
Net transfers from (to) separate accounts	21		24
Interest credited	140		146
Other	(3)		3
Balance, end of period	$	6,982	$	7,241

Weighted-average annual crediting rate	4.1 %		4.1 %

At period end:
Cash surrender value	$	6,456	$	6,696
Net amount at risk, excluding offsets from reinsurance (2):
In the event of death	$	58,904	$	62,364

(2)Including offsets from reinsurance, the net amount at risk at June 30, 2026 and 2025 would be reduced by 98% and 99%, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Policyholder Account Balances (continued)

Corporate & Other’s life and other products account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:


Range of GMCR	At GMCR		Greater than 0% but less than 0.50% above GMCR		Equal to or greater than 0.50% but less than 1.50% above GMCR		Equal to or greater than 1.50% above GMCR		Total Account Value
	(In millions)
June 30, 2026
Equal to or greater than 0% but less than 2%	$	—	$	—	$	—	$	—	$	—
Equal to or greater than 2% but less than 4%	362		167		588		139		1,256
Equal to or greater than 4%	4,669		382		1		20		5,072
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		654
Total	$	5,031	$	549	$	589	$	159	$	6,982

June 30, 2025
Equal to or greater than 0% but less than 2%	$	—	$	—	$	—	$	—	$	—
Equal to or greater than 2% but less than 4%	359		170		628		144		1,301
Equal to or greater than 4%	4,882		397		1		22		5,302
Products with either a fixed rate or no GMCR	N/A		N/A		N/A		N/A		638
Total	$	5,241	$	567	$	629	$	166	$	7,241

6. Market Risk Benefits

The Company establishes assets and liabilities for variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit, less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets.

The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at:


	June 30, 2026						December 31, 2025
	Asset		Liability		Net Liability (Asset)		Asset		Liability		Net Liability (Asset)
	(In millions)
Corporate & Other - Annuities	$	287	$	1,896	$	1,609	$	258	$	2,043	$	1,785
Other	203		339		136		200		363		163
Total	$	490	$	2,235	$	1,745	$	458	$	2,406	$	1,948

Rollforwards

The following information about the direct and assumed liabilities (assets) for MRBs includes a disaggregated rollforward. The products grouped within this rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Market Risk Benefits (continued)

Corporate & Other

Corporate & Other’s variable annuity products offer contract features whereby the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantee contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. Corporate & Other’s variable annuity products also include an in-force block of assumed variable annuity guarantees from a third party. Information regarding Corporate & Other’s variable annuity products (including assumed reinsurance) was as follows:


		Six Months Ended June 30,
		2026		2025
	(In millions)
Balance, beginning of period (1)		$	1,785	$	2,069

Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk		$	1,665	$	1,992
Transfer, beginning of period, before effect of cumulative changes in the instrument-specific credit risk (1)		—		(191)
Attributed fees collected		147		160
Benefit payments		(49)		(45)
Effect of changes in interest rates		(123)		26
Effect of changes in capital markets		(276)		(181)
Effect of changes in equity index volatility		48		(3)
Actual policyholder behavior different from expected behavior		124		139

Effect of foreign currency translation and other, net		(2)		67
Effect of changes in risk margin		(30)		(2)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk		1,504		1,962
Cumulative effect of changes in the instrument-specific credit risk		107		87
Effect of foreign currency translation on the cumulative instrument-specific credit risk		(2)		2
Balance, end of period		1,609		2,051
Less: Reinsurance recoverable		209		—
Balance, end of period, net of reinsurance		$	1,400	$	2,051

At period end:
Net amount at risk, excluding offsets from hedging and reinsurance (2):
In the event of death		$	2,116	$	2,418
At annuitization or exercise of other living benefits		$	697	$	711
Weighted-average attained age of contractholders:
In the event of death		73 years		72 years
At annuitization or exercise of other living benefits		72 years		72 years

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the six months ended June 30, 2025 have been updated to reflect this change. The transfer amount related to the balance at January 1, 2025 was ($165) million. See Note 1 for further information on the Strategic Reorganization.

(2)Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs, which are disclosed in “Corporate & Other – Annuities” in Note 5.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Market Risk Benefits (continued)

Significant Methodologies and Assumptions

The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in other comprehensive income (loss) (“OCI”).

The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates.

Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 11 for additional information on significant unobservable inputs.

The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc.

Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees.

These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Market Risk Benefits (continued)

Other

In addition to the disaggregated MRB product rollforward above, the Company offers other products with guaranteed minimum benefit features across various segments. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 11 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities (assets) was as follows:


	Six Months Ended June 30,
	2026		2025
	(In millions)
Balance, beginning of period (1)	$	163	$	140

Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk	$	160	$	126
Transfer, beginning of period, before effect of cumulative changes in the instrument-specific credit risk (1)	—		191
Attributed fees collected	29		32
Benefit payments	(9)		(10)
Effect of changes in interest rates	(33)		(17)
Effect of changes in capital markets	(50)		(28)
Effect of changes in equity index volatility	41		(1)
Actual policyholder behavior different from expected behavior	16		7

Effect of foreign currency translation and other, net	(12)		15
Effect of changes in risk margin	(2)		(1)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk	140		314
Cumulative effect of changes in the instrument-specific credit risk	(3)		(10)
Effect of foreign currency translation on the cumulative instrument-specific credit risk	(1)		2
Balance, end of period	136		306
Less: Reinsurance recoverable	8		15
Balance, end of period, net of reinsurance	$	128	$	291

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the six months ended June 30, 2025 have been updated to reflect this change. The transfer amount related to the balance at January 1, 2025 was $165 million. See Note 1 for further information on the Strategic Reorganization.

7. Separate Accounts

Separate account assets consist of investment accounts established and maintained by the Company. The investment objectives of these assets are directed by the contractholder. An equivalent amount is reported as separate account liabilities. These accounts are reported separately from the general account assets and liabilities.

Separate Account Liabilities

The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at:


	June 30, 2026		December 31, 2025
	(In millions)
RIS:
Stable value and risk solutions	$	38,165	$	38,925
Annuities	18,169		18,099
Latin America - Pensions	49,713		48,549
Corporate & Other - Annuities	19,258		19,621
Other	31,545		26,739
Total	$	156,850	$	151,933

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Separate Accounts (continued)

Rollforwards

The following information about the separate account liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business.

The separate account liabilities are primarily comprised of the following: RIS stable value and risk solutions contracts, RIS annuity participating and non-participating group contracts and group variable deferred annuities, Latin America savings-oriented pension product in Chile within the country’s mandatory individual capitalization pension system, and Corporate & Other variable annuities.

The balances of and changes in separate account liabilities were as follows:


	RIS Stable Value and Risk Solutions		RIS Annuities		Latin America Pensions		Corporate & Other Annuities
	(In millions)
Six Months Ended June 30, 2026
Balance, beginning of period	$	38,925	$	18,099	$	48,549	$	19,621
Premiums and deposits	1,059		135		4,018		34
Policy charges	(157)		(54)		(144)		(214)
Surrenders and withdrawals	(1,386)		(868)		(3,235)		(1,229)
Benefit payments	(104)		(22)		(1,240)		(225)
Investment performance	904		764		2,960		1,331
Net transfers from (to) general account	9		(10)		—		(59)
Effect of foreign currency translation and other, net (1)	(1,085)		125		(1,195)		(1)
Balance, end of period	$	38,165	$	18,169	$	49,713	$	19,258
Six Months Ended June 30, 2025
Balance, beginning of period	$	40,319	$	11,001	$	38,765	$	27,829
Transfer, January 1 (2)	—		6,926		—		(6,926)
Premiums and deposits	1,121		103		3,479		35
Policy charges	(140)		(51)		(137)		(230)
Surrenders and withdrawals	(3,258)		(787)		(2,565)		(1,257)
Benefit payments	(82)		(20)		(911)		(208)
Investment performance	1,416		879		2,597		1,082
Net transfers from (to) general account	30		(62)		—		(71)
Effect of foreign currency translation and other, net (1)	(2,478)		(151)		2,599		63
Balance, end of period	$	36,928	$	17,838	$	43,827	$	20,317

Cash surrender value at June 30, 2026 (3)	$	34,871	$	7,139	$	49,713	$	19,150
Cash surrender value at June 30, 2025 (3)	$	34,285	$	6,938	$	43,827	$	20,127

(1)The effect of foreign currency translation and other, net, for RIS stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities.

(2)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the six months ended June 30, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

(3)Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Separate Accounts (continued)

Separate Account Assets

The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at:


	June 30, 2026
	Group Benefits		RIS		Asia		Latin America		EMEA		Corporate & Other		Total
	(In millions)
Fixed maturity securities:
Bonds:
Government and agency	$	—	$	8,949	$	948	$	12,005	$	4,794	$	—	$	26,696
Public utilities	—		1,098		149		—		—		—		1,247
Municipals	—		276		19		—		—		—		295
Corporate bonds	—		8,048		781		8,292		393		—		17,514
Total bonds	—		18,371		1,897		20,297		5,187		—		45,752
Mortgage-backed securities	—		8,267		—		—		—		—		8,267
Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)	—		2,373		—		—		—		—		2,373
Redeemable preferred stock	—		7		175		—		—		—		182
Total fixed maturity securities	—		29,018		2,072		20,297		5,187		—		56,574
Equity securities	—		2,973		6,253		4,157		2,394		—		15,777
Mutual funds:
Bond funds	87		1,582		270		7,043		43		1,939		10,964
Equity funds	1,232		6,948		4,117		14,436		69		14,177		40,979
Balanced funds	89		104		—		—		—		3		196
Other	125		11,342		349		—		29		10,836		22,681
Total mutual funds	1,533		19,976		4,736		21,479		141		26,955		74,820
Other invested assets (1)	—		651		366		3,150		159		—		4,326
Total investments	1,533		52,618		13,427		49,083		7,881		26,955		151,497
Other assets	—		3,828		868		630		27		—		5,353
Total	$	1,533	$	56,446	$	14,295	$	49,713	$	7,908	$	26,955	$	156,850

(1)Other invested assets for Latin America includes derivatives. These derivatives are primarily interest rate swaps and foreign currency forward contracts used to manage capital market risks within the pension funds on behalf of the participants and are not designated as hedging instruments. Changes in the estimated fair value of these derivatives are offset by corresponding changes in separate account liabilities, as the investment performance of the related separate account assets accrues to the participants, and therefore do not have a material impact on the Company’s net income. These derivatives are subject to master netting agreements, and any collateral posting requirements are managed by the general account and not included in the table above. The Company recorded cash collateral received of $533 million at June 30, 2026 in connection with these derivatives, with a corresponding payable recorded within other liabilities.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Separate Accounts (continued)


	December 31, 2025
	Group Benefits		RIS		Asia		Latin America		EMEA		Corporate & Other		Total
	(In millions)
Fixed maturity securities:
Bonds:
Government and agency	$	—	$	9,257	$	1,128	$	12,336	$	4,326	$	—	$	27,047
Public utilities	—		1,077		173		—		—		—		1,250
Municipals	—		307		17		—		—		—		324
Corporate bonds	—		8,078		733		8,749		461		—		18,021
Total bonds	—		18,719		2,051		21,085		4,787		—		46,642
Mortgage-backed securities	—		8,306		—		—		—		—		8,306
ABS & CLO	—		2,388		—		—		—		—		2,388
Redeemable preferred stock	—		8		138		—		—		—		146
Total fixed maturity securities	—		29,421		2,189		21,085		4,787		—		57,482
Equity securities	—		2,889		3,698		4,261		1,953		—		12,801
Mutual funds:
Bond funds	87		1,270		191		5,657		44		2,041		9,290
Equity funds	1,156		6,561		3,366		13,495		169		13,782		38,529
Balanced funds	80		89		—		—		—		2		171
Other	115		10,673		336		—		68		11,097		22,289
Total mutual funds	1,438		18,593		3,893		19,152		281		26,922		70,279
Other invested assets	—		1,198		312		3,753		118		—		5,381
Total investments	1,438		52,101		10,092		48,251		7,139		26,922		145,943
Other assets	—		5,027		640		298		25		—		5,990
Total	$	1,438	$	57,128	$	10,732	$	48,549	$	7,164	$	26,922	$	151,933

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue

DAC and VOBA

Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows:


	Six Months Ended June 30, 2026
	Group Benefits		RIS		Asia (1)		Latin America (2)		EMEA (2)		Corporate & Other (3)		Total
	(In millions)
DAC:
Balance, beginning of period	$	250	$	785	$	11,643	$	2,343	$	2,021	$	2,691	$	19,733
Capitalizations	12		170		935		466		317		9		1,909
Amortization	(20)		(47)		(405)		(337)		(204)		(96)		(1,109)
Effect of foreign currency translation and other, net	—		—		(263)		63		(38)		(2)		(240)
Balance, end of period	$	242	$	908	$	11,910	$	2,535	$	2,096	$	2,602	$	20,293

VOBA:
Balance, beginning of period	$	—	$	10	$	875	$	393	$	91	$	5	$	1,374

Amortization	—		(1)		(29)		(22)		(5)		(1)		(58)
Effect of foreign currency translation and other, net	—		—		(30)		(6)		(2)		—		(38)
Balance, end of period	$	—	$	9	$	816	$	365	$	84	$	4	$	1,278

	Six Months Ended June 30, 2025
	Group Benefits		RIS		Asia (1)		Latin America (2)		EMEA (2)		Corporate & Other (3)		Total
	(In millions)
DAC:
Balance, beginning of period	$	250	$	552	$	10,785	$	1,836	$	1,664	$	3,091	$	18,178
Transfer, January 1 (4)	—		98		—		—		—		(98)		—
Capitalizations	12		83		769		348		262		11		1,485
Amortization	(13)		(39)		(417)		(247)		(178)		(106)		(1,000)
Effect of foreign currency translation and other, net	—		—		499		177		145		3		824
Balance, end of period	$	249	$	694	$	11,636	$	2,114	$	1,893	$	2,901	$	19,487

VOBA:
Balance, beginning of period	$	—	$	13	$	935	$	393	$	94	$	14	$	1,449

Amortization	—		(1)		(33)		(19)		(6)		(1)		(60)
Effect of foreign currency translation and other, net	—		—		81		27		9		—		117
Balance, end of period	$	—	$	12	$	983	$	401	$	97	$	13	$	1,506

Total DAC and VOBA:
Balance at June 30, 2026													$	21,571
Balance at June 30, 2025													$	20,993
Balance at December 31, 2025													$	21,107

(1)Includes DAC balances primarily related to accident & health, universal and variable universal life, variable life and fixed annuity products and VOBA balances primarily related to accident & health products.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue (continued)

(2)Includes DAC balances primarily related to universal life, variable universal life, ordinary life and accident & health products.

(3)Includes DAC balances primarily related to whole life, variable annuities, term life, universal life, and long-term care products. See Note 1 for further information on the Strategic Reorganization.

(4)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the six months ended June 30, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

Unearned Revenue

Information regarding the Company’s unearned revenue primarily related to interest sensitive whole life, variable life and universal life products by segment, as well as Corporate & Other, included in other policy-related balances was as follows:


	Six Months Ended June 30, 2026
	RIS		Asia		Latin America		EMEA		Corporate & Other (1)		Total
	(In millions)
Balance, beginning of period	$	23	$	3,346	$	997	$	723	$	73	$	5,162
Deferrals	1		231		77		55		5		369
Amortization	(3)		(117)		(65)		(39)		(2)		(226)
Effect of foreign currency translation and other, net	—		(36)		23		(5)		—		(18)
Balance, end of period	$	21	$	3,424	$	1,032	$	734	$	76	$	5,287

	Six Months Ended June 30, 2025
	RIS		Asia		Latin America		EMEA		Corporate & Other (1)		Total
	(In millions)
Balance, beginning of period	$	27	$	3,076	$	841	$	622	$	69	$	4,635
Deferrals	1		229		68		59		6		363
Amortization	(3)		(124)		(55)		(37)		(3)		(222)
Effect of foreign currency translation and other, net	—		52		81		39		—		172
Balance, end of period	$	25	$	3,233	$	935	$	683	$	72	$	4,948

(1)See Note 1 for information on the Strategic Reorganization.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments

Fixed Maturity Securities Available-for-Sale

Fixed Maturity Securities Available-for-Sale by Sector

The following table presents fixed maturity securities available-for-sale (“AFS”) by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, nonqualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans, broadly syndicated bank loans, and other assets. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.”


	June 30, 2026														December 31, 2025
							Gross Unrealized						Estimated Fair Value						Gross Unrealized				Estimated Fair Value
Sector	Amortized Cost		Allowance for Credit Loss (“ACL”)			Gains			Losses			Amortized Cost	ACL		Gains		Losses
	(In millions)
U.S. corporate	$	97,070		$	(108)		$	1,424		$	7,226		$	91,160	$	92,855	$	(138)	$	1,899	$	6,657	$	87,959
Foreign corporate	64,575			(35)			1,900			4,768			61,672		62,606		(7)		2,443		4,453		60,589
RMBS	47,495			(1)			531			2,046			45,979		46,567		(1)		822		1,970		45,418
Foreign government	47,870			(56)			886			8,476			40,224		47,037		(57)		1,068		7,300		40,748
U.S. government and agency	40,682			—			172			6,008			34,846		42,877		—		303		5,658		37,522
ABS & CLO	27,939			—			199			451			27,687		23,028		(6)		246		371		22,897
Municipals	11,997			—			198			1,378			10,817		12,195		—		225		1,356		11,064
CMBS	10,153			(24)			85			416			9,798		10,036		(40)		131		393		9,734
Total fixed maturity securities AFS	$	347,781		$	(224)		$	5,395		$	30,769		$	322,183	$	337,201	$	(249)	$	7,137	$	28,158	$	315,931

Maturities of Fixed Maturity Securities AFS

The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at June 30, 2026:


	Due in One Year or Less		Due After One Year Through Five Years		Due After Five Years Through Ten Years		Due After Ten Years		Structured Products		Total Fixed Maturity Securities AFS
	(In millions)
Amortized cost, net of ACL	$	11,145	$	52,069	$	59,819	$	138,962	$	85,562	$	347,557
Estimated fair value	$	11,256	$	51,861	$	58,802	$	116,800	$	83,464	$	322,183

Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector

The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position.


	June 30, 2026								December 31, 2025
	Less than 12 Months				Equal to or Greater than 12 Months				Less than 12 Months				Equal to or Greater than 12 Months
Sector & Credit Quality	Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses
	(Dollars in millions)
U.S. corporate	$	22,437	$	772	$	35,107	$	6,436	$	8,564	$	527	$	37,884	$	6,092
Foreign corporate	12,826		329		20,840		4,427		5,314		199		22,687		4,251
RMBS	13,934		197		10,915		1,850		3,848		69		12,983		1,902
Foreign government	11,093		950		15,860		7,525		9,716		652		16,214		6,646
U.S. government and agency	9,475		208		16,738		5,800		8,544		181		16,341		5,477
ABS & CLO	10,681		127		3,654		324		5,349		49		4,000		322
Municipals	1,170		86		5,089		1,292		1,000		79		5,147		1,277
CMBS	2,273		68		3,313		345		1,164		36		3,660		355
Total fixed maturity securities AFS	$	83,889	$	2,737	$	111,516	$	27,999	$	43,499	$	1,792	$	118,916	$	26,322
Investment grade	$	80,782	$	2,633	$	108,904	$	27,685	$	41,743	$	1,707	$	116,021	$	26,002
Below investment grade	3,107		104		2,612		314		1,756		85		2,895		320
Total fixed maturity securities AFS	$	83,889	$	2,737	$	111,516	$	27,999	$	43,499	$	1,792	$	118,916	$	26,322
Total number of securities in an unrealized loss position	8,452				9,256				5,489				9,850

Evaluation of Fixed Maturity Securities AFS for Credit Loss

Evaluation and Measurement Methodologies

See “Fixed Maturity Securities AFS — Evaluation of Fixed Maturity Securities AFS for Credit Loss — Evaluation and Measurement Methodologies” in Note 11 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report.

Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position

Gross unrealized losses on securities without an ACL increased $2.6 billion for the six months ended June 30, 2026 to $30.7 billion primarily due to an increase in interest rates.

As shown in the table above, most of the gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater at June 30, 2026, relate to investment grade securities. These unrealized losses are principally due to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase.

As of June 30, 2026, $314 million of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater on below investment grade securities were concentrated in the consumer, communications, and transportation sectors within corporate securities and in foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty and, with respect to fixed-rate securities, rising interest rates since purchase.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

At June 30, 2026, the Company did not intend to sell its securities in an unrealized loss position without an ACL, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Therefore, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at June 30, 2026.

Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation.

Rollforward of ACL for Fixed Maturity Securities AFS By Sector

The rollforward of ACL for fixed maturity securities AFS by sector was as follows:


	U.S. Corporate		Foreign Corporate		Foreign Government		RMBS		ABS & CLO		CMBS		Total
	(In millions)
Three Months Ended June 30, 2026
Balance, beginning of period	$	134	$	52	$	57	$	1	$	5	$	24	$	273
ACL not previously recorded	—		—		—		—		—		—		—
Changes for securities with previously recorded ACL	—		(4)		—		—		—		—		(4)
Securities sold or exchanged	(26)		(13)		(1)		—		(5)		—		(45)


Balance, end of period	$	108	$	35	$	56	$	1	$	—	$	24	$	224
Three Months Ended June 30, 2025
Balance, beginning of period	$	40	$	6	$	57	$	2	$	7	$	25	$	137
ACL not previously recorded	16		—		—		—		—		—		16
Changes for securities with previously recorded ACL	6		(2)		—		—		(2)		—		2
Securities sold or exchanged	—		(4)		—		—		—		—		(4)


Balance, end of period	$	62	$	—	$	57	$	2	$	5	$	25	$	151


	U.S. Corporate		Foreign Corporate		Foreign Government		RMBS		ABS & CLO		CMBS		Total
	(In millions)
Six Months Ended June 30, 2026
Balance, at beginning of period	$	138	$	7	$	57	$	1	$	6	$	40	$	249
ACL not previously recorded	—		52		—		—		—		4		56
Changes for securities with previously recorded ACL	22		(4)		—		—		(1)		4		21
Securities sold or exchanged	(52)		(20)		(1)		—		(5)		(24)		(102)


Balance, at end of period	$	108	$	35	$	56	$	1	$	—	$	24	$	224
Six Months Ended June 30, 2025
Balance, at beginning of period	$	59	$	18	$	57	$	1	$	9	$	16	$	160
ACL not previously recorded	16		—		—		1		—		7		24
Changes for securities with previously recorded ACL	13		(2)		—		—		(1)		2		12
Securities sold or exchanged	(26)		(16)		—		—		(3)		—		(45)


Balance, at end of period	$	62	$	—	$	57	$	2	$	5	$	25	$	151

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Equity Securities

The following table presents equity securities by security type:



	June 30, 2026							December 31, 2025
			Net Unrealized Gains (Losses) (1)			Estimated Fair Value				Net Unrealized Gains (Losses) (1)		Estimated Fair Value
Security Type	Cost				Cost
	(In millions)
Common stock (2)	$	569	$	253		$	822	$	498	$	246	$	744
Non-redeemable preferred stock	103		7			110		106		8		114
Total	$	672	$	260		$	932	$	604	$	254	$	858

(1) Represents cumulative changes in estimated fair value, recognized in earnings.

(2) Includes common stock, exchange-traded funds, certain mutual funds and certain real estate investment trusts.

Contractholder-Directed Equity Securities and FVO Securities

The following table presents these investments by asset type:


	June 30, 2026						December 31, 2025
Asset Type	Cost or Amortized Cost		Net Unrealized Gains (Losses) (1)		Estimated Fair Value		Cost or Amortized Cost		Net Unrealized Gains (Losses) (1)		Estimated Fair Value
	(In millions)
Contractholder-directed equity securities:
Equity securities	$	3,264	$	785	$	4,049	$	3,164	$	855	$	4,019
Series mutual funds and other securities	5,359		1,847		7,206		5,089		1,640		6,729
Total contractholder-directed equity securities	$	8,623	$	2,632	$	11,255	$	8,253	$	2,495	$	10,748
FVO securities:
Securities held by CFEs	$	1,546	$	(29)	$	1,517	$	1,283	$	—	$	1,283
General account and other securities	1,101		936		2,037		1,149		779		1,928
Total FVO securities:	$	2,647	$	907	$	3,554	$	2,432	$	779	$	3,211
Total	$	11,270	$	3,539	$	14,809	$	10,685	$	3,274	$	13,959

(1)Represents cumulative changes in estimated fair value, recognized in earnings.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Mortgage Loans

Mortgage Loans by Portfolio Segment

Mortgage loans are summarized as follows at:


	June 30, 2026				December 31, 2025
Portfolio Segment	Carrying Value (1)		% of Total		Carrying Value (1)		% of Total
	(Dollars in millions)
Commercial	$	45,948	55.4	%	$	49,400	58.4	%
Agricultural	19,777		23.9		19,551		23.1
Residential	18,489		22.3		16,800		19.9
Total amortized cost	84,214		101.6		85,751		101.4
ACL	(1,358)		(1.6)		(1,193)		(1.4)
Total mortgage loans held-for-investment	82,856		100.0		84,558		100.0


Mortgage loans held-for-sale	—		—		35		—
Total mortgage loans	$	82,856	100.0	%	$	84,593	100.0	%

(1)Includes certain mortgage loans originated for third parties of $5.8 billion and $6.5 billion at amortized cost, with the corresponding mortgage loan secured financing liability of $5.8 billion and $6.5 billion included in other liabilities on the consolidated balance sheet at June 30, 2026 and December 31, 2025, respectively.

The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($734) million and ($789) million at June 30, 2026 and December 31, 2025, respectively. The accrued interest income for commercial, agricultural and residential mortgage loans at June 30, 2026 was $163 million, $197 million and $159 million, respectively. The accrued interest income for commercial, agricultural and residential mortgage loans at December 31, 2025 was $172 million, $206 million and $140 million, respectively. The accrued interest income related to mortgage loans is included in accrued investment income on the interim condensed consolidated balance sheets.

Purchases of mortgage loans, consisting primarily of residential mortgage loans, were $1.6 billion and $3.0 billion for the three months and six months ended June 30, 2026, respectively, and $797 million and $1.7 billion for the three months and six months ended June 30, 2025, respectively.

Sales of mortgage loans were $34 million and $53 million for the three months and six months ended June 30, 2026, respectively.

For both the three months and six months ended June 30, 2025, the Company exchanged, as part of loan restructurings, commercial mortgage loans with an amortized cost of $172 million for equity interests in REJVs.

For the three months and six months ended June 30, 2026, the Company acquired wholly-owned real estate by completing foreclosures on commercial mortgage loans with an amortized cost of $91 million and $173 million, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Rollforward of ACL for Mortgage Loans by Portfolio Segment

The rollforward of ACL for mortgage loans, by portfolio segment, was as follows:


	Six Months Ended June 30,
	2026								2025
	Commercial		Agricultural		Residential		Total		Commercial		Agricultural		Residential		Total
	(In millions)
Balance, beginning of period	$	807	$	115	$	271	$	1,193	$	537	$	84	$	179	$	800
Provision (release)	348		1		(33)		316		410		10		27		447


Charge-offs, net of recoveries	(139)		(9)		(3)		(151)		(51)		—		—		(51)

Balance, end of period	$	1,016	$	107	$	235	$	1,358	$	896	$	94	$	206	$	1,196

The gross charge-offs of mortgage loans by origination year and portfolio segment for the six months ended June 30, 2026 were as follows:


Portfolio Segment	2026		2025		2024		2023		2022		Prior		Total
	(In millions)
Commercial	$	—	$	—	$	—	$	—	$	24	$	115	$	139
Agricultural	—		—		—		—		—		9		9
Residential	—		—		1		—		1		1		3

Total	$	—	$	—	$	1	$	—	$	25	$	125	$	151

ACL Methodology

The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses).

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Commercial and Agricultural Mortgage Loan Portfolio Segments

Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. In its evaluation, the Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for such loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans.

Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans.

For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio.

For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated.

After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Residential Mortgage Loan Portfolio Segment

The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year.

For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss.

Modifications to Borrowers Experiencing Financial Difficulty

The Company may modify mortgage loans to borrowers. Each mortgage loan modification is evaluated to determine whether the borrower was experiencing financial difficulties. Disclosed below are those modifications, in materially impacted mortgage segments, where the borrower was determined to be experiencing financial difficulties and the mortgage loans were modified by any of the following means: principal forgiveness, interest rate reduction, other-than-insignificant payment delay or maturity extension. The amount, timing and extent of modifications granted and subsequent performance are considered in determining any ACL recorded. All loans modified to borrowers experiencing financial difficulties are evaluated individually for credit loss as collateral dependent loans.

These mortgage loan modifications are summarized as follows:


	Three Months Ended June 30,
	2026
	Amortized Cost		Affected Loans (in Years)
Portfolio Segment	Maturity Extension			Payment Delay		Total		Weighted-Average Life Increase	Average Years Payment Deferral	% of Book Value
	(Dollars in millions)
Commercial	$	250		$	—	$	250	2 years			—	<1%


	Three Months Ended June 30,
	2025
	Amortized Cost		Affected Loans (in Years)
Portfolio Segment	Maturity Extension			Payment Delay		Total		Weighted-Average Life Increase	Average Years Payment Deferral	% of Book Value
	(Dollars in millions)
Commercial	$	339		$	—	$	339	5 years			—	<1%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)


	Six Months Ended June 30,
	2026
	Amortized Cost		Affected Loans (in Years)
Portfolio Segment	Maturity Extension			Payment Delay		Total		Weighted-Average Life Increase	Average Years Payment Deferral	% of Book Value
	(Dollars in millions)
Commercial	$	250		$	—	$	250	2 years			$	—	<1%


	Six Months Ended June 30,
	2025
	Amortized Cost		Affected Loans (in Years)
Portfolio Segment	Maturity Extension			Payment Delay		Total		Weighted-Average Life Increase	Average Years Payment Deferral	% of Book Value
	(Dollars in millions)
Commercial	$	589		$	—	$	589	5 years			$	—	1.1	%

For the three months and six months ended June 30, 2026 and 2025, all commercial mortgage loans modified within the past 12 months to borrowers experiencing financial difficulties and still outstanding were current.

Credit Quality of Mortgage Loans by Portfolio Segment

The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2026:


Credit Quality Indicator	2026		2025		2024		2023		2022		Prior		Revolving Loans		Total		% of Total
	(Dollars in millions)
LTV ratios:
Less than 65%	$	1,445	$	2,596	$	3,125	$	1,890	$	2,152	$	12,180	$	1,577	$	24,965	54.3	%
65% to 75%	264		401		542		630		2,231		3,378		—		7,446		16.2
76% to 80%	1		150		—		63		334		2,135		—		2,683		5.9
Greater than 80%	3		135		190		—		705		9,821		—		10,854		23.6
Total	$	1,713	$	3,282	$	3,857	$	2,583	$	5,422	$	27,514	$	1,577	$	45,948	100.0	%
DSCR:
> 1.20x	$	1,394	$	2,856	$	3,352	$	2,030	$	4,488	$	22,793	$	1,577	$	38,490	83.8	%
1.00x - 1.20x	45		374		6		428		392		2,502		—		3,747		8.1
<1.00x	274		52		499		125		542		2,219		—		3,711		8.1
Total	$	1,713	$	3,282	$	3,857	$	2,583	$	5,422	$	27,514	$	1,577	$	45,948	100.0	%

The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2026:


Credit Quality Indicator	2026		2025		2024		2023		2022		Prior		Revolving Loans		Total		% of Total
	(Dollars in millions)
LTV ratios:
Less than 65%	$	1,120	$	1,300	$	679	$	1,169	$	2,118	$	10,485	$	1,316	$	18,187	92.0	%
65% to 75%	—		119		47		77		284		761		57		1,345		6.8
76% to 80%	—		—		—		—		22		11		4		37		0.2
Greater than 80%	18		—		12		—		146		22		10		208		1.0
Total	$	1,138	$	1,419	$	738	$	1,246	$	2,570	$	11,279	$	1,387	$	19,777	100.0	%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2026:


Credit Quality Indicator	2026		2025		2024		2023		2022		Prior		Revolving Loans		Total		% of Total
	(Dollars in millions)
Performance indicators:
Performing	$	1,487	$	3,607	$	1,940	$	685	$	2,055	$	8,178	$	—	$	17,952	97.1	%
Nonperforming (1)	1		38		73		52		92		281		—		537		2.9
Total	$	1,488	$	3,645	$	2,013	$	737	$	2,147	$	8,459	$	—	$	18,489	100.0	%

(1)Includes residential mortgage loans in process of foreclosure with an amortized cost of $197 million and $186 million at June 30, 2026 and December 31, 2025, respectively.

Past Due and Nonaccrual Mortgage Loans

The Company has a high quality, well performing mortgage loan portfolio, with 98% of all mortgage loans classified as performing at both June 30, 2026 and December 31, 2025. The Company defines delinquency in a manner consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows:


	Past Due				Past Due and Still Accruing Interest				Nonaccrual
Portfolio Segment	June 30, 2026		December 31, 2025		June 30, 2026		December 31, 2025		June 30, 2026		December 31, 2025
	(In millions)
Commercial	$	821	$	682	$	—	$	3	$	1,685	$	1,915
Agricultural	237		252		6		66		242		225
Residential	537		523		24		23		513		500
Total	$	1,595	$	1,457	$	30	$	92	$	2,440	$	2,640

Real Estate and REJVs

The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method REJVs. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated:


					Three Months Ended June 30,				Six Months Ended June 30,
	June 30, 2026		December 31, 2025		2026		2025			2026		2025
Income Type	Carrying Value				Income
	(In millions)
Wholly-owned real estate:
Leased real estate	$	4,221	$	4,174	$	106	$	89		$	191	$	178
Other real estate	712		710		93		96			168		171
REJVs	8,132		8,556		49		54			115		97
Total real estate and REJVs	$	13,065	$	13,440	$	248	$	239		$	474	$	446

Depreciation expense on real estate investments was $40 million and $69 million for the three months and six months ended June 30, 2026, respectively, and $28 million and $57 million for the three months and six months ended June 30, 2025, respectively. Real estate investments were net of accumulated depreciation of $1.1 billion at both June 30, 2026 and December 31, 2025.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Leased Real Estate Investments — Operating Leases

The Company, as lessor, leases investment real estate, principally commercial real estate for office and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification and geographic diversification.

See Note 11 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for a summary of leased real estate investments and earned income by property type.

Other Invested Assets

Tax Equity Investments

The Company invests in certain tax equity investments, including low income housing tax credit partnerships and renewable energy partnerships. The carrying value of tax equity investments, reported in other invested assets on the interim condensed consolidated balance sheets, was $1.1 billion and $676 million at June 30, 2026 and December 31, 2025, respectively. For the three months and six months ended June 30, 2026, income tax credits and other income tax benefits of $31 million and $57 million, respectively, and amortized expenses of $27 million and $49 million, respectively, were recognized net as a component of income tax expense on the Company’s interim condensed consolidated statements of operations. For the three months and six months ended June 30, 2025, income tax credits and other income tax benefits of $31 million and $59 million, respectively, and amortized expenses of $34 million and $57 million, respectively, were recognized net as a component of income tax expense on the Company’s interim condensed consolidated statements of operations.

Cash Equivalents

Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was $7.6 billion and $11.5 billion, at estimated fair value, at June 30, 2026 and December 31, 2025, respectively.

Concentrations of Credit Risk

Investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value, were in fixed income securities of the following foreign governments and their agencies:


	June 30, 2026		December 31, 2025
	(In millions)
Japan	$	14,987	$	16,265
South Korea	$	4,632	$	5,971
Mexico	$	4,888	$	4,190

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Securities Lending Transactions and Repurchase Agreements

Securities, Collateral and Reinvestment Portfolio

Transactions and agreements accounted for as secured borrowings were as follows:


		June 30, 2026						December 31, 2025
		Securities (1)						Securities (1)
Agreement Type		Estimated Fair Value		Cash Collateral Received from Counterparties (2)		Reinvestment Portfolio at Estimated Fair Value		Estimated Fair Value		Cash Collateral Received from Counterparties (2)		Reinvestment Portfolio at Estimated Fair Value
	(In millions)
Securities lending		$	12,628	$	13,034	$	12,987	$	11,866	$	12,198	$	12,082
Repurchase agreements		$	3,352	$	3,275	$	3,254	$	3,002	$	2,975	$	2,948

(1)These securities were included within fixed maturity securities AFS, short-term investments and cash equivalents at both June 30, 2026 and December 31, 2025. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge these securities.

(2)The liability for cash collateral is included within payables for collateral under securities loaned and other transactions.

Contractual Maturities

Contractual maturities of transactions and agreements accounted for as secured borrowings were as follows:


	June 30, 2026										December 31, 2025
	Remaining Maturities										Remaining Maturities
Cash collateral liability by security type:	Open (1)		1 Month or Less		Over 1 Month to 6 Months		Over 6 Months to 1 Year		Total		Open (1)		1 Month or Less		Over 1 Month to 6 Months		Over 6 Months to 1 Year		Total
	(In millions)
Securities lending:
U.S. government and agency	$	2,224	$	4,359	$	5,186	$	—	$	11,769	$	1,986	$	3,911	$	4,880	$	—	$	10,777
Foreign government	—		984		—		—		984		—		755		355		—		1,110
Agency RMBS	—		281		—		—		281		—		311		—		—		311


Total	$	2,224	$	5,624	$	5,186	$	—	$	13,034	$	1,986	$	4,977	$	5,235	$	—	$	12,198

Repurchase agreements:
U.S. government and agency	$	—	$	3,275	$	—	$	—	$	3,275	$	—	$	2,975	$	—	$	—	$	2,975

(1)The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.

If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell investments to meet the return obligation, it may have difficulty selling such collateral that is invested in a timely manner, be forced to sell investments in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both.

The securities lending and repurchase agreement reinvestment portfolios consist principally of high quality, liquid, publicly traded fixed maturity securities AFS, short-term investments, cash equivalents or cash. If the securities in the reinvestment portfolio become less liquid, liquidity resources within the general account are available to meet any potential cash demands when securities are put back by the counterparty.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

Invested Assets on Deposit, Held in Trust and Pledged as Collateral

Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value, and were as follows at:


	June 30, 2026		December 31, 2025
	(In millions)
Invested assets on deposit (regulatory deposits)	$	1,548	$	1,396
Invested assets held in trust (external reinsurance agreements) (1)	5,380		1,775
Invested assets pledged as collateral (2)	29,877		27,663
Total invested assets on deposit, held in trust and pledged as collateral	$	36,805	$	30,834

(1)Represents assets held in trust related to assumed third-party reinsurance agreements. Excludes assets held in trust related to reinsurance agreements between wholly-owned subsidiaries of $1.8 billion at both June 30, 2026 and December 31, 2025.

(2)The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements, repurchase agreements and a collateral financing arrangement (see Notes 5, 16 and 17 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report). For information regarding invested assets pledged in connection with derivative transactions, see Note 10.

See “— Securities Lending Transactions and Repurchase Agreements” for information regarding securities supporting securities lending transactions and repurchase agreements. In addition, the Company’s investment in Federal Home Loan Bank of New York common stock, included within other invested assets, which is considered restricted until redeemed by the issuer, was $702 million and $700 million at redemption value at June 30, 2026 and December 31, 2025, respectively.

The Company maintained invested assets and cash and cash equivalents that are subject to ceded reinsurance arrangements with third parties and joint ventures of $22.6 billion and $22.4 billion at June 30, 2026 and December 31, 2025, respectively, which includes cash and cash equivalents of $469 million and $1.2 billion at June 30, 2026 and December 31, 2025, respectively.

Variable Interest Entities

The Company has invested in legal entities that are VIEs. Legal entities are determined to be VIEs if (1) the equity investors lack (i) the ability to control the entity, (ii) the obligation to absorb losses or (iii) the rights to receive returns of the entity, or (2) the entity lacks sufficient equity to finance its activities without subordinated financial support.

For VIEs, the Company determines whether it is the primary beneficiary, which involves an evaluation of the purpose and design of the entity and whether, based on the design of the entity, the Company has both (1) the power to direct the activities of the entity which most significantly affect the economic performance of the entity and (2) the obligation to absorb losses or the right to receive benefits that are potentially significant to the VIE. Significant judgment is required in the primary beneficiary determination, which includes an evaluation of the substance of contractual arrangements and voting agreements, the rights of other investors in an entity and the potential financial results of the entity.

The Company continuously assesses if facts or circumstances indicate that a potential change in the primary beneficiary has occurred. This could include new contractual arrangements of an entity or changes in the investors of an entity. As a result of changes in circumstances, the Company may consolidate or deconsolidate a VIE.

Consolidated VIEs

The Company is the asset manager of certain CFEs, primarily collateralized loan obligations (“CLOs”), for which the Company earns asset management fees. The Company may invest in securities issued by these entities. The Company is also the asset manager of certain investment fund structures and partnership entities in which the Company also invests.

The Company has analyzed its relationships with the CLOs, investment fund structures and partnership entities and determined that it is the primary beneficiary of certain of these entities, which requires the Company to consolidate them as VIEs. This analysis includes a review of the rights and responsibilities as the asset manager, the rights of the investors in the entity, and the exposure of the Company to the potential losses and returns of the entity.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

The Company is also the primary beneficiary of certain investment funds and partnership entities in which the Company has invested but is not the asset manager.

The assets of the VIEs may only be used to satisfy the liabilities of the respective VIEs. The Company is not required to, and has not provided, material financial support to the VIEs, other than its investment in these VIEs.

The table below reflects the carrying amount and balance sheet classification in which the assets and liabilities of consolidated VIEs are reported. The liabilities primarily comprise debt instruments issued by the VIEs. The creditors of these VIEs do not have recourse to the Company in excess of the assets contained within the respective VIEs.


	June 30, 2026		December 31, 2025			June 30, 2026		December 31, 2025
Instrument Type	Consolidated VIEs for which the Company is the Asset Manager				Other Consolidated VIEs
	(In millions)
FVO securities primarily held by CFEs	$	1,531	$	1,300		$	—	$	—
Contractholder-directed equity securities	454		451			—		—
Real estate and REJVs	236		81			195		221
Investment funds (1)	583		490			—		—
Renewable energy partnership (1)	—		—			40		45
Leases (1)	—		25			—		—
Cash and cash equivalents	350		90			7		6
Other	40		21			29		34
Total assets of consolidated VIEs	$	3,194	$	2,458		$	271	$	306
Short-term debt	$	—	$	—		$	114	$	117
Long-term debt	69		28			—		—
Notes issued by CFEs	1,497		1,206			—		—
Other liabilities	367		158			7		9
Total liabilities of consolidated VIEs	$	1,933	$	1,392		$	121	$	126

(1)Included in other invested assets.

Unconsolidated VIEs

The Company has determined that it is not the primary beneficiary of certain VIEs because the Company does not have both (1) the power to direct the activities of the entity which most significantly affect the economic performance of the entity and (2) the obligation to absorb losses or the right to receive benefits that are potentially significant to the VIE.

The Company invests in structured products issued by CFEs or securitization entities that are VIEs which typically do not have substantial equity. Its investments in these structured products are fixed maturity securities investments and include mortgage-backed securities, and ABS & CLOs. The Company’s exposure to losses of these entities is limited to the amount of its investment. See “— Fixed Maturity Securities Available-for-Sale” for details regarding amounts and classification of these assets.

The Company also invests in or provides loans to other legal entities that are VIEs. These primarily include hedge funds, private equity funds and similar entities that are classified within OLPIs, REJVs, other invested assets, fixed maturity securities, FVO securities and mortgage loans. The Company’s maximum exposure to loss for these VIEs is limited to the carrying value of the equity investment plus any unfunded capital commitments. The carrying value of these investments was $25.6 billion and $24.6 billion at June 30, 2026 and December 31, 2025, respectively, and the Company’s unfunded commitments were $6.1 billion and $6.2 billion at June 30, 2026 and December 31, 2025, respectively.

In connection with a certain reinsurance agreement, collateral securing the reinsurance agreement was transferred to trusts that do not have substantial equity. For managing these assets, MIM will recognize asset management fees which represent a variable interest. The Company’s maximum exposure to loss is limited to the asset management fee revenue that has been earned but not yet received.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

The Company did not provide financial or other support that it was not contractually obligated to provide to entities designated as VIEs for the six months ended June 30, 2026 or 2025.

Net Investment Income

The composition of net investment income by asset type was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
Asset Type	2026		2025		2026		2025
	(In millions)
Fixed maturity securities AFS (1)	$	4,094	$	3,608	$	7,994	$	7,075
Equity securities	4		3		10		12
FVO securities	185		107		155		87
Mortgage loans (1)	1,097		1,104		2,176		2,243
Policy loans	108		113		217		220
Real estate and REJVs	248		239		474		446
OLPI (1)	138		124		596		344
Cash, cash equivalents and short-term investments (1)	217		254		441		504
Operating joint ventures	85		38		84		58
Other	84		100		304		339
Subtotal investment income	6,260		5,690		12,451		11,328
Less: Investment expenses	556		527		1,074		1,053
Subtotal, net	5,704		5,163		11,377		10,275
Unit-linked investments	998		498		680		271
Net investment income	$	6,702	$	5,661	$	12,057	$	10,546

Net Investment Income Information
Net realized and unrealized gains (losses) recognized in net investment income:
Net realized gains (losses) from sales and disposals (primarily FVO securities and Unit-linked investments)	$	270	$	102	$	441	$	145
Net unrealized gains (losses) from changes in estimated fair value (primarily FVO securities and Unit-linked investments)	814		452		265		163
Net realized and unrealized gains (losses) recognized in net investment income	$	1,084	$	554	$	706	$	308

Changes in estimated fair value subsequent to purchase of FVO securities and Unit-linked investments still held at the end of the respective periods and recognized in net investment income	$	988	$	532	$	595	$	248

Equity method investments net investment income (primarily REJVs, OLPI, tax credit and renewable energy partnerships and operating joint ventures)	$	282	$	238	$	815	$	505

(1)Includes net investment income related to invested assets and cash and cash equivalents that are subject to ceded reinsurance with third parties.

Net Investment Gains (Losses)

Net Investment Gains (Losses) by Instrument Type and Transaction Type

The composition of net investment gains (losses) by instrument type and transaction type was as follows:

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)


	Three Months Ended June 30,				Six Months Ended June 30,
Instrument Type	2026		2025		2026		2025
	(In millions)
Fixed maturity securities AFS	$	(231)	$	(124)	$	(442)	$	(368)
Equity securities	20		45		4		33
FVO securities	(32)		—		(32)		—
Mortgage loans	(200)		(269)		(326)		(461)
Real estate and REJVs (excluding changes in estimated fair value)	7		3		(114)		3
OLPI (excluding changes in estimated fair value) (1)	3		21		(41)		20
Notes issued by CFEs	12		—		12		—
Other gains (losses)	24		(33)		(8)		(38)
Subtotal	(397)		(357)		(947)		(811)
Change in estimated fair value of OLPI and REJVs	1		(3)		4		—
Non-investment portfolio gains (losses)	(32)		87		(155)		151
Subtotal	(31)		84		(151)		151
Net investment gains (losses)	$	(428)	$	(273)	$	(1,098)	$	(660)

Transaction Type
Realized gains (losses) on investments sold or disposed (1)	$	(238)	$	(145)	$	(480)	$	(446)
Impairment (losses)	(57)		(2)		(196)		(7)
Recognized gains (losses):
Change in ACL recognized in earnings	(100)		(272)		(255)		(431)
Unrealized net gains (losses) recognized in earnings	(1)		59		(12)		73
Total recognized gains (losses)	(101)		(213)		(267)		(358)
Non-investment portfolio gains (losses)	(32)		87		(155)		151
Net investment gains (losses)	$	(428)	$	(273)	$	(1,098)	$	(660)

Net Investment Gains (Losses) Information
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)	$	20	$	46	$	9	$	38
Changes in estimated fair value subsequent to purchase of FVO securities still held at the end of the respective periods and recognized in net investment gains (losses)	$	(28)	$	—	$	(28)	$	—
Changes in estimated fair value subsequent to recognition of Notes issued by CFEs still outstanding at the end of the respective periods and recognized in net investment gains (losses)	$	12	$	—	$	12	$	—

Other gains (losses) include:
Gains (losses) on disposed investments which were previously in a qualified cash flow hedging relationship	$	(15)	$	10	$	(15)	$	9
Gains (losses) on leveraged leases and renewable energy partnerships	$	20	$	—	$	20	$	—

Foreign currency gains (losses)	$	47	$	70	$	(85)	$	145

Net Realized Investment Gains (Losses) From Sales and Disposals of Investments
Recognized in net investment gains (losses)	$	(238)	$	(145)	$	(480)	$	(446)
Recognized in net investment income	270		102		441		145
Net realized investment gains (losses) from sales and disposals of investments	$	32	$	(43)	$	(39)	$	(301)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Investments (continued)

(1)Includes a net loss of $51 million and $2 million for the six months ended June 30, 2026 and 2025, respectively, for private equity investments sold. For the six months ended June 30, 2026 and 2025, the Company sold $745 million and $43 million, respectively, in portfolios of investments to funds for proceeds of $694 million and $41 million, respectively, in cash and receivables secured by the value of the respective funds. The Company has entered into agreements to serve as the asset manager of the funds for which it receives management fees.

Fixed Maturity Securities AFS and Equity Securities — Composition of Net Investment Gains (Losses)

The composition of net investment gains (losses) for these securities was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
Fixed Maturity Securities AFS	2026		2025		2026		2025
	(In millions)
Proceeds	$	11,520	$	6,143	$	22,521	$	13,384
Gross investment gains	$	133	$	63	$	251	$	149
Gross investment (losses)	(414)		(171)		(719)		(522)
Realized gains (losses) on sales and disposals	(281)		(108)		(468)		(373)
Net credit loss (provision) release (change in ACL recognized in earnings)	50		(14)		29		10
Impairment (losses)	—		(2)		(3)		(5)
Net credit loss (provision) release and impairment (losses)	50		(16)		26		5
Net investment gains (losses)	$	(231)	$	(124)	$	(442)	$	(368)

Equity Securities
Realized gains (losses) on sales and disposals	$	4	$	(18)	$	(3)	$	(40)
Unrealized net gains (losses) recognized in earnings	16		63		7		73
Net investment gains (losses)	$	20	$	45	$	4	$	33

10. Derivatives

Accounting for Derivatives

See Note 1 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for a description of the Company’s accounting policies for derivatives and Note 11 for information about the fair value hierarchy for derivatives.

Types of Derivative Instruments and Derivative Strategies

The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to:

Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic GICs;
Foreign currency exchange rate derivatives: swaps, forwards, options and exchange-traded futures;
Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and
Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps.

For detailed information on these contracts and the related strategies, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

Primary Risks Managed by Derivatives

The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at:


			June 30, 2026							December 31, 2025
					Estimated Fair Value								Estimated Fair Value
	Primary Underlying Risk Exposure	Gross Notional Amount	Assets		Liabilities		Gross Notional Amount		Assets			Liabilities
			(In millions)
Derivatives Designated as Hedging Instruments:
Fair value hedges:
Interest rate swaps	Interest rate		$	4,986	$	910	$	712		$	4,924		$	923	$	706
Foreign currency swaps	Foreign currency exchange rate		4,480		71		19			1,607			33		22

Subtotal			9,466		981		731			6,531			956		728
Cash flow hedges:
Interest rate swaps	Interest rate		3,754		—		256			4,002			—		267
Interest rate forwards	Interest rate		4,009		—		1,073			4,389			16		1,049
Foreign currency swaps	Foreign currency exchange rate		47,039		2,290		2,065			47,097			2,358		2,184
Subtotal			54,802		2,290		3,394			55,488			2,374		3,500
Net investment in a foreign operation (“NIFO”) hedges:
Foreign currency forwards	Foreign currency exchange rate		1,209		30		6			1,052			32		10
Currency options	Foreign currency exchange rate		3,000		325		—			3,000			264		—
Subtotal			4,209		355		6			4,052			296		10
Total qualifying hedges			68,477		3,626		4,131			66,071			3,626		4,238
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate swaps	Interest rate		24,151		1,355		1,579			24,623			1,409		1,434
Interest rate floors	Interest rate		5,390		33		—			5,640			34		—
Interest rate caps	Interest rate		15,147		84		2			14,898			48		1
Interest rate futures	Interest rate		2,111		2		6			1,679			1		3
Interest rate options	Interest rate		22,923		172		94			23,820			155		130
Interest rate forwards	Interest rate		1,724		—		276			2,731			16		176

Synthetic GICs	Interest rate		52,056		—		—			52,664			—		—
Foreign currency swaps	Foreign currency exchange rate		11,423		1,242		143			10,210			1,167		175
Foreign currency forwards	Foreign currency exchange rate		13,967		81		673			15,694			85		1,012
Currency futures	Foreign currency exchange rate		283		1		2			292			—		1

Credit default swaps — purchased	Credit		2,646		1		51			2,739			2		58
Credit default swaps — written	Credit		15,523		260		3			8,873			153		1
Equity futures	Equity market		1,086		10		7			1,380			5		2
Equity index options	Equity market		17,937		682		353			16,253			337		281
Equity variance swaps	Equity market		96		—		2			96			—		2
Equity total return swaps	Equity market		1,367		—		91			2,413			7		34
Longevity swaps	Longevity		1,000		—		—			1,000			—		—
Total non-designated or nonqualifying derivatives			188,830		3,923		3,282			185,005			3,419		3,310
Total			$	257,307	$	7,549	$	7,413		$	251,076		$	7,045	$	7,548

Included in the table above, the Company uses various over-the-counter (“OTC”) and exchange traded derivatives to hedge variable annuity guarantees. The table below presents the primary underlying risk exposure, gross notional amount and estimated fair value of the derivatives hedging variable annuity guarantees accounted for as MRBs:

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)


		June 30, 2026							December 31, 2025
				Estimated Fair Value								Estimated Fair Value
Primary Underlying Risk Exposure	Gross Notional Amount	Assets		Liabilities		Gross Notional Amount		Assets			Liabilities
		(In millions)
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate		$	8,535	$	17	$	557		$	8,450		$	10	$	524
Foreign currency exchange rate		217		—		3			328			2		9
Equity market		2,626		272		119			2,844			152		104
		$	11,378	$	289	$	679		$	11,622		$	164	$	637

The change in estimated fair values and earned income of derivatives hedging variable annuity guarantees, recorded in net derivative gains (losses), was ($166) million and ($130) million for the six months ended June 30, 2026 and 2025, respectively.

Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at either June 30, 2026 or December 31, 2025. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge MRBs that do not qualify for hedge accounting because the changes in estimated fair value of the MRBs are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, NIFO, nonqualifying hedging relationships and embedded derivatives:


	Three Months Ended June 30, 2026
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to PABs		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	1	$	—	N/A		$	(33)	$	(27)	$	—	N/A
Hedged items	(1)		—		N/A		28		26		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	78		(2)		N/A		—		—		—		N/A
Hedged items	(78)		1		N/A		—		3		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		—		N/A		—		—		—		(89)
Subtotal	—		(1)		N/A		(5)		2		—		(89)
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	(96)
Amount of gains (losses) reclassified from AOCI into income	1		(16)		—		—		—		—		15
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		(339)
Amount of gains (losses) reclassified from AOCI into income	—		(116)		—		—		—		—		116
Foreign currency transaction gains (losses) on hedged items	—		110		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		—
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	1		(22)		—		—		—		—		(304)
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		—		N/A		N/A		N/A		N/A		40
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		5
Subtotal	N/A		—		N/A		N/A		N/A		N/A		45
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	—		N/A		(202)		N/A		N/A		N/A		N/A
Foreign currency exchange rate derivatives (1)	—		N/A		(336)		N/A		N/A		N/A		N/A
Credit derivatives — purchased (1)	—		N/A		(6)		N/A		N/A		N/A		N/A
Credit derivatives — written (1)	—		N/A		65		N/A		N/A		N/A		N/A
Equity derivatives (1)	(48)		N/A		(480)		N/A		N/A		N/A		N/A
Foreign currency transaction gains (losses) on hedged items	—		N/A		99		N/A		N/A		N/A		N/A
Subtotal	(48)		N/A		(860)		N/A		N/A		N/A		N/A
Earned income on derivatives	(4)		—		177		7		(37)		—		—
Synthetic GICs	N/A		N/A		20		N/A		N/A		N/A		N/A
Embedded derivatives - ceded reinsurance	N/A		N/A		14		N/A		N/A		N/A		N/A
Embedded derivatives - other	N/A		N/A		(123)		N/A		N/A		N/A		N/A
Total	$	(51)	$	(23)	$	(772)	$	2	$	(35)	$	—	$	(348)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)


	Three Months Ended June 30, 2025
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to PABs		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	—	$	—	N/A		$	2	$	11	$	—	N/A
Hedged items	—		—		N/A		(8)		(12)		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	(18)		5		N/A		—		87		—		N/A
Hedged items	17		(4)		N/A		—		(87)		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		(1)		N/A		—		—		—		N/A
Subtotal	(1)		—		N/A		(6)		(1)		—		N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	(235)
Amount of gains (losses) reclassified from AOCI into income	6		9		—		—		—		—		(15)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		(801)
Amount of gains (losses) reclassified from AOCI into income	1		1,086		—		—		—		—		(1,087)
Foreign currency transaction gains (losses) on hedged items	—		(1,091)		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		—
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	7		4		—		—		—		—		(2,138)
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		—		N/A		N/A		N/A		N/A		(71)
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		(9)
Subtotal	N/A		—		N/A		N/A		N/A		N/A		(80)
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	—		N/A		(272)		N/A		N/A		N/A		N/A
Foreign currency exchange rate derivatives (1)	—		N/A		(317)		N/A		N/A		N/A		N/A
Credit derivatives — purchased (1)	—		N/A		(6)		N/A		N/A		N/A		N/A
Credit derivatives — written (1)	—		N/A		38		N/A		N/A		N/A		N/A
Equity derivatives (1)	(28)		N/A		(441)		N/A		N/A		N/A		N/A
Foreign currency transaction gains (losses) on hedged items	—		N/A		99		N/A		N/A		N/A		N/A
Subtotal	(28)		N/A		(899)		N/A		N/A		N/A		N/A
Earned income on derivatives	(9)		—		106		2		(34)		—		—
Synthetic GICs	N/A		N/A		21		N/A		N/A		N/A		N/A
Embedded derivatives - ceded reinsurance	N/A		N/A		(22)		N/A		N/A		N/A		N/A
Embedded derivatives - other	N/A		N/A		(2)		N/A		N/A		N/A		N/A
Total	$	(31)	$	4	$	(796)	$	(4)	$	(35)	$	—	$	(2,218)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)


	Six Months Ended June 30, 2026
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to PABs		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	1	$	—	N/A		$	(39)	$	(41)	$	—	N/A
Hedged items	(1)		—		N/A		30		40		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	54		(2)		N/A		—		(7)		—		N/A
Hedged items	(54)		1		N/A		—		10		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		—		N/A		—		—		—		(23)
Subtotal	—		(1)		N/A		(9)		2		—		(23)
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	(106)
Amount of gains (losses) reclassified from AOCI into income	2		(15)		—		—		—		—		13
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		110
Amount of gains (losses) reclassified from AOCI into income	1		(365)		—		—		—		—		364
Foreign currency transaction gains (losses) on hedged items	—		350		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		—
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	3		(30)		—		—		—		—		381
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		—		N/A		N/A		N/A		N/A		108
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		9
Subtotal	N/A		—		N/A		N/A		N/A		N/A		117
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	—		N/A		(294)		N/A		N/A		N/A		N/A
Foreign currency exchange rate derivatives (1)	—		N/A		(381)		N/A		N/A		N/A		N/A
Credit derivatives — purchased (1)	—		N/A		(1)		N/A		N/A		N/A		N/A
Credit derivatives — written (1)	—		N/A		3		N/A		N/A		N/A		N/A
Equity derivatives (1)	(32)		N/A		(531)		N/A		N/A		N/A		N/A
Foreign currency transaction gains (losses) on hedged items	—		N/A		91		N/A		N/A		N/A		N/A
Subtotal	(32)		N/A		(1,113)		N/A		N/A		N/A		N/A
Earned income on derivatives	83		—		277		14		(76)		—		—
Synthetic GICs	N/A		N/A		39		N/A		N/A		N/A		N/A
Embedded derivatives - ceded reinsurance	N/A		N/A		205		N/A		N/A		N/A		N/A
Embedded derivatives - other	N/A		N/A		(106)		N/A		N/A		N/A		N/A
Total	$	54	$	(31)	$	(698)	$	5	$	(74)	$	—	$	475

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)


	Six Months Ended June 30, 2025
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to PABs		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	(1)	$	—	N/A		$	77	$	53	$	—	N/A
Hedged items	1		—		N/A		(87)		(52)		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	(28)		13		N/A		—		123		—		N/A
Hedged items	27		(10)		N/A		—		(123)		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		(4)		N/A		—		—		—		N/A
Subtotal	(1)		(1)		N/A		(10)		1		—		N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	(122)
Amount of gains (losses) reclassified from AOCI into income	23		9		—		—		—		—		(32)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		(680)
Amount of gains (losses) reclassified from AOCI into income	3		1,446		—		—		—		—		(1,449)
Foreign currency transaction gains (losses) on hedged items	—		(1,449)		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		—
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	26		6		—		—		—		—		(2,283)
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		—		N/A		N/A		N/A		N/A		(143)
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		(23)
Subtotal	N/A		—		N/A		N/A		N/A		N/A		(166)
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	—		N/A		(174)		N/A		N/A		N/A		N/A
Foreign currency exchange rate derivatives (1)	—		N/A		(72)		N/A		N/A		N/A		N/A
Credit derivatives — purchased (1)	—		N/A		(15)		N/A		N/A		N/A		N/A
Credit derivatives — written (1)	—		N/A		11		N/A		N/A		N/A		N/A
Equity derivatives (1)	(11)		N/A		(382)		N/A		N/A		N/A		N/A
Foreign currency transaction gains (losses) on hedged items	—		N/A		68		N/A		N/A		N/A		N/A
Subtotal	(11)		N/A		(564)		N/A		N/A		N/A		N/A
Earned income on derivatives	86		—		216		4		(74)		—		—
Synthetic GICs	N/A		N/A		40		N/A		N/A		N/A		N/A
Embedded derivatives - ceded reinsurance	N/A		N/A		(57)		N/A		N/A		N/A		N/A
Embedded derivatives - other	N/A		N/A		1		N/A		N/A		N/A		N/A
Total	$	100	$	5	$	(364)	$	(6)	$	(73)	$	—	$	(2,449)

(1)Excludes earned income on derivatives.

Fair Value Hedges

The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities, and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

The following table presents the balance sheet classification, carrying amount and cumulative fair value of hedging adjustments for items designated and qualifying as hedged items in fair value hedges:


	June 30, 2026		December 31, 2025		June 30, 2026		December 31, 2025
Balance Sheet Line Item	Carrying Amount of the Hedged Assets/(Liabilities)				Cumulative Amount of Fair Value Hedging Adjustments Included in the Carrying Amount of Hedged Assets/(Liabilities) (1)
	(In millions)
Fixed maturity securities AFS	$	3,779	$	658	$	—	$	—
Mortgage loans	$	29	$	51	$	(1)	$	—
FPBs	$	(2,404)	$	(2,509)	$	357	$	319
PABs	$	(2,412)	$	(2,559)	$	151	$	(9)

(1)Includes ($57) million and ($67) million of hedging adjustments on discontinued hedging relationships at June 30, 2026 and December 31, 2025, respectively.

For the Company’s foreign currency forwards, changes in estimated fair value attributable to the difference between spot price and forward price are excluded from hedge effectiveness testing and are recognized in earnings. For certain foreign currency swaps, changes in estimated fair value related to cross-currency basis spreads are excluded from the effectiveness assessment and recorded in OCI. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

Cash Flow Hedges

The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments.

In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were ($13) million and ($9) million for the three months and six months ended June 30, 2026, respectively, and $2 million and $14 million for the three months and six months ended June 30, 2025, respectively.

At both June 30, 2026 and December 31, 2025, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed three years.

At June 30, 2026 and December 31, 2025, the balance in AOCI associated with cash flow hedges was ($1.7) billion and ($2.1) billion, respectively.

All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

At June 30, 2026, the Company expected to reclassify ($96) million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months.

NIFO Hedges

The Company uses foreign currency exchange rate derivatives, which may include foreign currency forwards and currency options, to hedge portions of its NIFO against adverse movements in exchange rates. The Company also designates a portion of its foreign-denominated debt as a non-derivative hedging instrument of its NIFO. The Company assesses hedge effectiveness of its derivatives based upon the change in forward rates and assesses its non-derivative hedging instruments based upon the change in spot rates. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

When NIFOs are sold or substantially liquidated, the amounts in AOCI are reclassified to the statements of operations.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

At June 30, 2026 and December 31, 2025, the cumulative foreign currency translation gain (loss) recorded in AOCI related to NIFO hedges was $1.3 billion and $1.2 billion, respectively. At June 30, 2026 and December 31, 2025, the carrying amount of debt designated as a non-derivative hedging instrument was $258 million and $268 million, respectively.

Credit Derivatives

In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps.

The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at:


	June 30, 2026					December 31, 2025
Rating Agency Designation of Referenced Credit Obligations (1)	Estimated Fair Value of Credit Default Swaps		Maximum Amount of Future Payments under Credit Default Swaps		Weighted Average Years to Maturity (2)	Estimated Fair Value of Credit Default Swaps		Maximum Amount of Future Payments under Credit Default Swaps		Weighted Average Years to Maturity (2)
	(Dollars in millions)
Aaa/Aa/A
Single name credit default swaps (3)	$	1	$	31	3.1	$	1	$	59	2.5
Credit default swaps referencing indices	31		3,777		0.9	44		3,777		1.4
Subtotal	32		3,808		0.9	45		3,836		1.4
Baa
Single name credit default swaps (3)	1		56		3.2	1		46		3.8
Credit default swaps referencing indices	203		11,331		5.6	95		4,807		4.6
Subtotal	204		11,387		5.6	96		4,853		4.6
Ba

Credit default swaps referencing indices	—		24		0.5	1		24		1.0
Subtotal	—		24		0.5	1		24		1.0
B
Single name credit default swaps (3)	—		3		0.5	—		16		0.6
Credit default swaps referencing indices	21		286		3.9	10		129		3.0
Subtotal	21		289		3.8	10		145		2.7
Caa

Credit default swaps referencing indices	—		15		0.5	—		15		1.0
Subtotal	—		15		0.5	—		15		1.0
Total	$	257	$	15,523	4.4	$	152	$	8,873	3.2

(1)The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service, Inc. (“Moody’s”), Standard & Poor’s Global Ratings (“S&P”) and Fitch Ratings Inc. If no rating is available from a rating agency, then an internally developed rating is used.

(2)The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.

(3)Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

Credit Risk on Freestanding Derivatives

The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements.

The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law.

The Company’s OTC derivatives are cleared and settled through central clearing counterparties (“OTC-cleared”) and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives.

See Note 11 for a description of the impact of credit risk on the valuation of derivatives.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at:


	June 30, 2026				December 31, 2025
Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement	Assets		Liabilities		Assets		Liabilities
	(In millions)
Gross estimated fair value of derivatives:
OTC-bilateral (1)	$	7,390	$	6,722	$	7,053	$	6,972
OTC-cleared (1)	262		728		119		569
Exchange-traded	13		15		6		6
Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1)	7,665		7,465		7,178		7,547
Gross amounts not offset on the interim condensed consolidated balance sheets:
Gross estimated fair value of derivatives: (2)
OTC-bilateral	(3,110)		(3,110)		(3,015)		(3,015)
OTC-cleared	(16)		(16)		(7)		(7)
Exchange-traded	(1)		(1)		—		—
Cash collateral: (3), (4)
OTC-bilateral	(2,270)		—		(1,808)		—
OTC-cleared	(230)		(680)		(105)		(555)
Exchange-traded	—		(2)		—		(1)
Securities collateral: (5)
OTC-bilateral	(1,978)		(3,553)		(2,211)		(3,945)
OTC-cleared	—		(32)		—		(6)
Exchange-traded	—		(12)		—		(5)
Net amount after application of master netting agreements and collateral	$	60	$	59	$	32	$	13

(1)At June 30, 2026 and December 31, 2025, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $116 million and $133 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $52 million and ($1) million, respectively.

(2)Gross estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.

(3)Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives.

(4)The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At June 30, 2026 and December 31, 2025, the Company received excess cash collateral of $73 million and $29 million, respectively, and provided excess cash collateral of $76 million and $68 million, respectively, which is not included in the table above due to the foregoing limitation.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

(5)Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at June 30, 2026, none of the collateral had been sold and $5 million was re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At June 30, 2026 and December 31, 2025, the Company received excess securities collateral with an estimated fair value of $393 million and $381 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At both June 30, 2026 and December 31, 2025, the Company provided excess securities collateral with an estimated fair value of $1.3 billion for its OTC-bilateral derivatives, $752 million and $751 million, respectively, for its OTC-cleared derivatives, and $280 million and $215 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.

The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. A small number of these arrangements also contain credit-contingent provisions that include a threshold below which collateral does not need to be posted. Such agreements provide for a reduction of these thresholds (on a sliding scale that converges toward zero) in the event of downgrades in the financial strength or credit ratings of the Company and/or the counterparty (or its guarantor, as applicable). At June 30, 2026, the amount of collateral not provided by the Company due to the existence of these thresholds was $15 million.

The Company’s netting agreements for derivatives generally contain provisions that require the counterparty (or its guarantor, if applicable) to maintain specified minimum credit ratings above investment grade level from Moody’s, S&P or both. In those agreements, if the credit rating of the counterparty (or its guarantor, if applicable) were to fall below the applicable minimum rating, that counterparty would be in violation of these provisions, and the Company could terminate the transactions and demand immediate settlement and payment based on reasonable valuation of the derivatives. A significant portion of the Company’s netting agreements for derivatives grant similar rights to the counterparty to terminate the transactions and demand immediate settlement and payment if the Company’s financial strength or credit rating were to fall below specified minimum levels above investment grade.

The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged.


	June 30, 2026						December 31, 2025
	Derivatives Subject to Credit- Contingent Provisions		Derivatives Not Subject to Credit- Contingent Provisions		Total		Derivatives Subject to Credit- Contingent Provisions		Derivatives Not Subject to Credit- Contingent Provisions		Total
	(In millions)
Estimated fair value of derivatives in a net liability position	$	3,612	$	—	$	3,612	$	3,946	$	11	$	3,957
Estimated fair value of collateral provided:
Fixed maturity securities AFS	$	4,190	$	—	$	4,190	$	4,661	$	11	$	4,672

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Derivat****ives (continued)

Embedded Derivatives

The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives.

The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at:


	Balance Sheet Location	June 30, 2026		December 31, 2025
		(In millions)


Embedded derivatives within liability host contracts:


Funds withheld on ceded reinsurance (1)	Other liabilities	$	(228)	$	(10)
Fixed annuities with equity indexed returns	PABs	396		67

Total		$	168	$	57

(1)Includes ($78) million and $81 million at June 30, 2026 and December 31, 2025, respectively, related to Chariot Reinsurance, Ltd. (“Chariot Re”). See Note 19 for additional related party transactions.

11. Fair Value

Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts.

Recurring Fair Value Measurements

The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at:

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


	June 30, 2026
	Fair Value Hierarchy
	Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate	$	—	$	76,507	$	14,653	$	91,160
Foreign corporate	—		44,105		17,567		61,672
RMBS	—		44,636		1,343		45,979
Foreign government	—		40,167		57		40,224
U.S. government and agency	15,638		19,208		—		34,846
ABS & CLO	—		25,983		1,704		27,687
Municipals	—		10,817		—		10,817
CMBS	—		9,377		421		9,798
Total fixed maturity securities AFS	15,638		270,800		35,745		322,183
Equity securities	439		146		347		932
Contractholder-directed equity securities and FVO securities:
Contractholder-directed equity securities	8,028		2,780		447		11,255
FVO securities	602		1,531		1,421		3,554
Total contractholder-directed equity securities and FVO securities:	8,630		4,311		1,868		14,809
Short-term investments (1)	6,483		1,217		62		7,762
Other investments	51		—		1,185		1,236
Derivative assets: (2)
Interest rate	2		2,554		—		2,556
Foreign currency exchange rate	1		4,009		30		4,040
Credit	—		261		—		261
Equity market	10		682		—		692
Total derivative assets	13		7,506		30		7,549
MRBs	—		—		490		490
Reinsured MRBs (3)	—		—		217		217
Separate account assets (4)	81,612		74,464		774		156,850
Total assets (5)	$	112,866	$	358,444	$	40,718	$	512,028
Liabilities
Derivative liabilities: (2)
Interest rate	$	6	$	3,992	$	—	$	3,998
Foreign currency exchange rate	2		2,903		3		2,908
Credit	—		54		—		54
Equity market	7		437		9		453
Total derivative liabilities	15		7,386		12		7,413
Embedded derivatives within liability host contracts (6)	—		—		168		168
Notes issued by CFEs	—		—		1,497		1,497
MRBs	—		—		2,235		2,235
Total liabilities	$	15	$	7,386	$	3,912	$	11,313

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


	December 31, 2025
	Fair Value Hierarchy
	Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate	$	—	$	74,437	$	13,522	$	87,959
Foreign corporate	—		43,761		16,828		60,589
RMBS	—		43,491		1,927		45,418
Foreign government	—		40,696		52		40,748
U.S. government and agency	18,732		18,790		—		37,522
ABS & CLO	—		21,747		1,150		22,897
Municipals	—		11,063		1		11,064
CMBS	—		9,318		416		9,734
Total fixed maturity securities AFS	18,732		263,303		33,896		315,931
Equity securities	464		77		317		858
Contractholder-directed equity securities and FVO securities:
Contractholder-directed equity securities	7,983		2,571		194		10,748
FVO securities	623		1,323		1,265		3,211
Total contractholder-directed equity securities and FVO securities:	8,606		3,894		1,459		13,959
Short-term investments (1)	2,761		537		42		3,340
Other investments	46		—		1,137		1,183
Derivative assets: (2)
Interest rate	1		2,601		—		2,602
Foreign currency exchange rate	—		3,905		34		3,939
Credit	—		155		—		155
Equity market	5		344		—		349
Total derivative assets	6		7,005		34		7,045
MRBs	—		—		458		458
Reinsured MRBs (3)	—		—		293		293
Separate account assets (4)	77,488		73,554		891		151,933
Total assets (5)	$	108,103	$	348,370	$	38,527	$	495,000
Liabilities
Derivative liabilities: (2)
Interest rate	$	3	$	3,763	$	—	$	3,766
Foreign currency exchange rate	1		3,403		—		3,404
Credit	—		59		—		59
Equity market	2		316		1		319
Total derivative liabilities	6		7,541		1		7,548
Embedded derivatives within liability host contracts (6)	—		—		57		57
Notes issued by CFEs	—		—		1,206		1,206
MRBs	—		—		2,406		2,406
Total liabilities	$	6	$	7,541	$	3,670	$	11,217

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

(1)Short-term investments as presented in the tables above differ from the amounts presented on the interim condensed consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis.

(2)Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.

(3)Reinsured MRBs are presented within premiums, reinsurance and other receivables on the interim condensed consolidated balance sheets.

(4)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities.

(5)Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $37 million and $41 million at June 30, 2026 and December 31, 2025, respectively.

(6)Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets.

The following describes the valuation methodologies used to measure assets and liabilities at fair value.

Investments

Securities, Short-term Investments and Other Investments

When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings, and valuation of these securities does not involve management’s judgment.

When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based, in large part, on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments.

The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein.

The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g., cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


Instrument	Level 2 Observable Inputs			Level 3 Unobservable Inputs
Fixed maturity securities AFS
U.S. corporate and Foreign corporate securities
	Valuation Approaches: Principally the market and income approaches.			Valuation Approaches: Principally the market approach.
	Key Inputs:			Key Inputs:
	•	quoted prices in markets that are not active		•	illiquidity premium
	•	benchmark yields; spreads off benchmark yields; new issuances; issuer ratings		•	delta spread adjustments to reflect specific credit-related issues
	•	trades of identical or comparable securities; duration		•	credit spreads
	•	privately-placed securities are valued using the additional key inputs:		•	quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
		•	market yield curve; call provisions	•	independent non-binding broker quotations
		•	observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer
		•	delta spread adjustments to reflect specific credit-related issues
Foreign government securities, U.S. government and agency securities and Municipals
	Valuation Approaches: Principally the market approach.			Valuation Approaches: Principally the market approach.
	Key Inputs:			Key Inputs:
	•	quoted prices in markets that are not active		•	independent non-binding broker quotations
	•	benchmark U.S. Treasury yield or other yields		•	quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
	•	the spread off the U.S. Treasury yield curve for the identical security		•	credit spreads
	•	issuer ratings and issuer spreads; broker-dealer quotations
	•	comparable securities that are actively traded
Structured Products
	Valuation Approaches: Principally the market and income approaches.			Valuation Approaches: Principally the market and income approaches.
	Key Inputs:			Key Inputs:
	•	quoted prices in markets that are not active		•	credit spreads
	•	spreads for actively traded securities; spreads off benchmark yields		•	quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
	•	expected prepayment speeds and volumes		•	independent non-binding broker quotations
	•	current and forecasted loss severity; ratings; geographic region		•	credit ratings
	•	weighted average coupon and weighted average maturity
	•	average delinquency rates; DSCR
	•	credit ratings
	•	issuance-specific information, including, but not limited to:
		•	collateral type; structure of the security; vintage of the loans
		•	payment terms of the underlying assets
		•	payment priority within the tranche; deal performance

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


Instrument	Level 2 Observable Inputs			Level 3 Unobservable Inputs
Equity securities
	Valuation Approaches: Principally the market approach.			Valuation Approaches: Principally the market and income approaches.
	Key Input:			Key Inputs:
	•	quoted prices in markets that are not considered active		•	credit ratings; issuance structures
				•	quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
				•	independent non-binding broker quotations
Contractholder-directed equity securities and FVO securities, Short-term investments and Other investments
	Valuation Approaches: Principally the market and income approaches.			Valuation Approaches: Principally the market and income approaches.
	Key Inputs:			Key Inputs:
	•	Contractholder-directed equity securities and FVO securities include mutual fund interests without readily determinable fair values given prices are not published publicly. Valuation of these mutual funds is based upon quoted prices or reported NAV provided by the fund managers, which were based on observable inputs.		•	Contractholder-directed equity securities and FVO securities, short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments also include certain REJVs and use the valuation approach and key inputs as described for OLPI below.
	•	Short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and observable inputs used in their valuation are also similar to those described above.








Separate account assets and Separate account liabilities (1)
Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly
	Key Input:			•	N/A
	•	quoted prices or reported NAV provided by the fund managers
OLPI
	•	N/A		Valued giving consideration to the underlying holdings of the partnerships and adjusting, if appropriate.
			Key Input:

			•	NAV

(1)Estimated fair value equals carrying value, based on the value of the underlying assets, including mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, OLPI, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”

Derivatives

The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.

The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. With respect to certain OTC-bilateral and OTC-cleared derivatives, management may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives.

Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

The credit risk of both the counterparty and the Company is considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by the counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period.

Freestanding Derivatives

Level 2 Valuation Approaches and Key Inputs:

This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3.

Level 3 Valuation Approaches and Key Inputs:

These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data.

Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows:


Instrument		Interest Rate		Foreign Currency Exchange Rate		Credit		Equity Market
Inputs common to Level 2 and Level 3 by instrument type	•	swap yield curves	•	swap yield curves	•	swap yield curves	•	swap yield curves
•	basis curves	•	basis curves	•	credit curves	•	spot equity index levels
•	interest rate volatility (1)	•	currency spot rates	•	recovery rates	•	dividend yield curves
			•	cross currency basis curves			•	equity volatility (1)
			•	currency volatility (1)
Level 3	•	N/A	•	swap yield curves (2)	•	N/A	•	dividend yield curves (2)
			•	basis curves (2)			•	equity volatility (1), (2)
			•	cross currency basis curves (2)			•	correlation between model inputs (1)
			•	currency correlation
			•	currency volatility (1)

(1)Option-based only.

(2)Extrapolation beyond the observable limits of the curve(s).

Embedded Derivatives

Embedded derivatives principally include equity-indexed annuity contracts and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their funds withheld hosts, in other liabilities on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.

The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk.

Notes Issued by CFEs

The estimated fair value of these notes is based on the estimated fair value of the corresponding securities which collateralize the notes. Since the notes are valued based on referenced collateral, they are classified as Level 3.

MRBs

See Note 6 for information on the Company’s valuation approaches and key inputs for MRBs.

Transfers between Levels

Overall, transfers between levels occur when there are changes in the observability of inputs and market activity.

Transfers into or out of Level 3:

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at:


					June 30, 2026				December 31, 2025				Impact of Increase in Input on Estimated Fair Value (2)
	Valuation Techniques		Significant Unobservable Inputs		Range			Weighted Average (1)	Range			Weighted Average (1)
Fixed maturity securities AFS (3)
U.S. corporate and foreign corporate	•	Matrix pricing	•	Offered quotes (4)	2	-	124	98	32	-	127	94	Increase
	•	Market pricing	•	Quoted prices (4)	—	-	107	96	—	-	100	91	Increase
	•	Consensus pricing	•	Offered quotes (4)	—	-	100	90	—	-	101	92	Increase
RMBS	•	Market pricing	•	Quoted prices (4)	31	-	110	96	33	-	114	96	Increase (5)
ABS & CLO	•	Market pricing	•	Quoted prices (4)	—	-	139	101	3	-	142	101	Increase (5)

Derivatives


Foreign currency exchange rate	•	Present value techniques	•	Swap yield (6)	166	-	225	207	154	-	203	202	Increase (7)


MRBs and Reinsured MRBs
Direct, assumed and ceded guaranteed minimum benefits	•	Option pricing techniques	•	Mortality rates:
				Ages 0 - 40	0%	-	0.15%	0.05%	0%	-	0.15%	0.05%	(8)
				Ages 41 - 60	0.04%	-	0.79%	0.22%	0.04%	-	0.79%	0.22%	(8)
				Ages 61 - 115	0%	-	100%	1.23%	0%	-	100%	1.23%	(8)
			•	Lapse rates:
				Durations 1 - 10	0.15%	-	20.10%	13.37%	0.15%	-	20.10%	13.37%	Decrease (9)
				Durations 11 - 20	0.38%	-	15%	8.17%	0.38%	-	15%	8.17%	Decrease (9)
				Durations 21 - 116	0.38%	-	15%	7.48%	0.38%	-	15%	7.48%	Decrease (9)





			•	Utilization rates	0.20%	-	16.25%	0.54%	0.20%	-	16.25%	0.54%	Increase (10)
			•	Withdrawal rates	0%	-	20%	4.92%	0%	-	20%	4.92%	(11)
			•	Long-term equity volatilities	14.29%	-	22.49%	18.96%	14.29%	-	22.49%	18.96%	Increase (12)
			•	Nonperformance risk spread	0.11%	-	1.59%	0.58%	0.10%	-	1.41%	0.58%	Decrease (13)

(1)The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data.

(2)The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions.

(3)Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations.

(4)Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par.

(5)Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.

(6)Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.

(7)Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

(8)Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on Company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates results in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates results in a decrease (increase) in the estimated fair value of MRBs.

(9)Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(10)The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(11)The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.

(12)Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(13)Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs.

All other classes of securities classified within Level 3, including those within contractholder-directed equity securities and FVO securities (collectively, “Unit-linked and FVO securities”), Other investments, Separate account assets, Notes issued by CFEs, and Embedded derivatives within funds withheld related to certain ceded reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. Generally, all other classes of assets and liabilities classified within Level 3 that are not included above use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.”

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 6):


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Fixed Maturity Securities AFS
	Corporate (6)		Foreign Government		Structured Products		Equity Securities		Contractholder-directed Equity Securities and FVO Securities
	(In millions)
Three Months Ended June 30, 2026
Balance, beginning of period	$	31,190	$	698	$	4,063	$	348	$	1,515
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	9		—		11		1		163
Total realized/unrealized gains (losses) included in AOCI	224		1		(25)		—		—
Purchases (3)	2,121		1		1,032		16		140
Sales (3)	(992)		(5)		(88)		(2)		(130)
Issuances (3)	—		—		—		—		—
Settlements (3)	—		—		—		—		—
Transfers into Level 3 (4)	53		11		102		—		200
Transfers out of Level 3 (4)	(385)		(649)		(1,627)		(16)		(20)
Balance, end of period	$	32,220	$	57	$	3,468	$	347	$	1,868
Three Months Ended June 30, 2025
Balance, beginning of period	$	27,512	$	57	$	4,807	$	248	$	1,175
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	(10)		—		7		16		94
Total realized/unrealized gains (losses) included in AOCI	872		1		11		—		—
Purchases (3)	1,154		7		511		20		95
Sales (3)	(479)		—		(182)		(32)		(99)
Issuances (3)	—		—		—		—		—
Settlements (3)	—		—		—		—		—
Transfers into Level 3 (4)	156		—		215		—		—
Transfers out of Level 3 (4)	(568)		(9)		(1,669)		—		—
Balance, end of period	$	28,637	$	56	$	3,700	$	252	$	1,265
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2026 (5)	$	17	$	—	$	10	$	8	$	149
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2025 (5)	$	(17)	$	—	$	9	$	16	$	94
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2026 (5)	$	195	$	1	$	(27)	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2025 (5)	$	873	$	1	$	10	$	—	$	—

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Short-term Investments		Other Investments		Net Derivatives (7)		Net Embedded Derivatives (8)		Separate Accounts (9)		Notes Issued by CFEs
	(In millions)
Three Months Ended June 30, 2026
Balance, beginning of period	$	101	$	1,133	$	36	$	152	$	794	$	(1,138)
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	—		55		(15)		(185)		2		12
Total realized/unrealized gains (losses) included in AOCI	—		—		—		—		—		—
Purchases (3)	22		11		—		—		17		—
Sales (3)	(4)		(14)		—		—		(39)		—
Issuances (3)	—		—		—		(140)		—		(574)
Settlements (3)	—		—		—		5		—		203
Transfers into Level 3 (4)	—		—		—		—		—		—
Transfers out of Level 3 (4)	(57)		—		(3)		—		—		—
Balance, end of period	$	62	$	1,185	$	18	$	(168)	$	774	$	(1,497)
Three Months Ended June 30, 2025
Balance, beginning of period	$	9	$	1,121	$	21	$	(43)	$	972	$	—
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	—		(18)		(4)		(24)		(19)		—
Total realized/unrealized gains (losses) included in AOCI	—		—		—		—		—		—
Purchases (3)	5		61		—		—		97		—
Sales (3)	—		(31)		—		—		(69)		—
Issuances (3)	—		—		—		—		—		—
Settlements (3)	—		—		—		157		—		—
Transfers into Level 3 (4)	—		20		—		—		1		—
Transfers out of Level 3 (4)	(6)		—		(1)		—		(5)		—
Balance, end of period	$	8	$	1,153	$	16	$	90	$	977	$	—
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2026 (5)	$	—	$	49	$	(15)	$	(186)	$	—	$	12
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2025 (5)	$	—	$	(32)	$	(4)	$	(24)	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2026 (5)	$	—	$	—	$	—	$	—	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2025 (5)	$	—	$	—	$	—	$	—	$	—	$	—

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Fixed Maturity Securities AFS
	Corporate (6)		Foreign Government		Structured Products		Equity Securities		Contractholder-directed Equity Securities and FVO Securities
	(In millions)
Six Months Ended June 30, 2026
Balance, beginning of period	$	30,350	$	52	$	3,493	$	317	$	1,459
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	10		—		5		12		80
Total realized/unrealized gains (losses) included in AOCI	(352)		—		(45)		—		—
Purchases (3)	3,907		2		1,178		30		265
Sales (3)	(1,462)		(1)		(291)		(13)		(118)
Issuances (3)	—		—		—		—		—
Settlements (3)	—		—		—		—		—
Transfers into Level 3 (4)	85		5		144		1		200
Transfers out of Level 3 (4)	(318)		(1)		(1,016)		—		(18)
Balance, end of period	$	32,220	$	57	$	3,468	$	347	$	1,868
Six Months Ended June 30, 2025
Balance, beginning of period	$	26,505	$	41	$	8,639	$	236	$	1,190
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	(28)		—		(12)		9		76
Total realized/unrealized gains (losses) included in AOCI	1,313		5		(78)		—		—
Purchases (3)	2,093		12		1,217		30		102
Sales (3)	(950)		(1)		(359)		(23)		(103)
Issuances (3)	—		—		—		—		—
Settlements (3)	—		—		—		—		—
Transfers into Level 3 (4)	95		—		169		—		—
Transfers out of Level 3 (4)	(391)		(1)		(5,876)		—		—
Balance, end of period	$	28,637	$	56	$	3,700	$	252	$	1,265
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2026 (5)	$	10	$	—	$	4	$	12	$	66
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2025 (5)	$	(19)	$	—	$	10	$	15	$	81
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2026 (5)	$	(375)	$	—	$	(48)	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2025 (5)	$	1,289	$	5	$	45	$	—	$	—

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Short-term Investments		Other Investments		Net Derivatives (7)		Net Embedded Derivatives (8)		Separate Accounts (9)		Notes Issued by CFEs
	(In millions)
Six Months Ended June 30, 2026
Balance, beginning of period	$	42	$	1,137	$	33	$	(57)	$	891	$	(1,206)
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	—		(35)		(9)		114		(9)		12
Total realized/unrealized gains (losses) included in AOCI	(3)		—		(1)		—		—		—
Purchases (3)	34		142		—		—		37		—
Sales (3)	(5)		(59)		—		—		(116)		—
Issuances (3)	—		—		—		(232)		—		(574)
Settlements (3)	—		—		—		7		—		271
Transfers into Level 3 (4)	—		—		—		—		1		—
Transfers out of Level 3 (4)	(6)		—		(5)		—		(30)		—
Balance, end of period	$	62	$	1,185	$	18	$	(168)	$	774	$	(1,497)
Six Months Ended June 30, 2025
Balance, beginning of period	$	5	$	1,010	$	5	$	(9)	$	990	$	—
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	—		(16)		11		(56)		(14)		—
Total realized/unrealized gains (losses) included in AOCI	1		—		1		—		—		—
Purchases (3)	6		208		—		—		103		—
Sales (3)	(3)		(69)		—		—		(92)		—
Issuances (3)	—		—		—		—		—		—
Settlements (3)	—		—		(1)		155		—		—
Transfers into Level 3 (4)	—		20		—		—		1		—
Transfers out of Level 3 (4)	(1)		—		—		—		(11)		—
Balance, end of period	$	8	$	1,153	$	16	$	90	$	977	$	—
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2026 (5)	$	—	$	(38)	$	(10)	$	113	$	—	$	12
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2025 (5)	$	—	$	(32)	$	10	$	(56)	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2026 (5)	$	—	$	—	$	—	$	—	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2025 (5)	$	1	$	—	$	—	$	—	$	—	$	—

(1)Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of Unit-linked and FVO securities are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(2)Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.

(3)Items purchased/issued and then sold/settled in the same period are excluded from the rollforward.

(4)Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

(5)Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(6)Comprised of U.S. and foreign corporate securities.

(7)Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.

(8)Embedded derivative assets and liabilities are presented net for purposes of the rollforward.

(9)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss).

Fair Value Option

The Company has elected the FVO for certain invested assets held by, and notes issued by, CFEs.

The unpaid principal balance on the invested assets held by CFEs exceeded the estimated fair value by $68 million and $33 million at June 30, 2026 and December 31, 2025, respectively.

The unpaid principal balance on the notes issued by CFEs exceeded the estimated fair value by $16 million and $1 million at June 30, 2026 and December 31, 2025, respectively.

Nonrecurring Fair Value Measurements

The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3).


	June 30, 2026		December 31, 2025
	(In millions)
Carrying value after measurement:
Mortgage loans (1)	$	1,699	$	1,583
Real estate and REJVs (2)	$	237	$	—


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
	(In millions)
Net investment gains (losses):
Mortgage loans (1)	$	(187)	$	(241)	$	(351)	$	(412)

Real estate and REJVs (2)	$	(58)	$	—	$	(194)	$	—

(1)Estimated fair values of impaired mortgage loans are based on the underlying collateral or discounted cash flows. See Note 9.

(2)Estimated fair values of impaired real estate and REJVs are based on appraised values.

Fair Value of Financial Instruments Carried at Other Than Fair Value

The following tables provide fair value information for financial instruments that are carried on the balance sheet at amounts other than fair value. The following tables exclude cash and cash equivalents, which are primarily classified as Level 1, and accrued investment income, payables for collateral under securities loaned and other transactions, short-term debt and those short-term investments that are not securities (i.e., time deposits), which are primarily classified as Level 2. The Company believes that due to the short-term nature of these excluded financial instruments, the estimated fair value approximates carrying value.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Fair Value (continued)

The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at:


	June 30, 2026
			Fair Value Hierarchy
	Carrying Value		Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Mortgage loans	$	82,856	$	—	$	—	$	80,570	$	80,570
Policy loans	$	8,226	$	—	$	—	$	8,679	$	8,679

Other invested assets	$	1,221	$	—	$	701	$	520	$	1,221
Premiums, reinsurance and other receivables	$	9,722	$	—	$	1,592	$	7,946	$	9,538
Other assets	$	232	$	—	$	40	$	193	$	233
Liabilities
PABs	$	155,163	$	—	$	—	$	151,349	$	151,349
Long-term debt	$	14,237	$	—	$	13,579	$	—	$	13,579
Collateral financing arrangement	$	286	$	—	$	—	$	265	$	265
Subordinated debt securities	$	5,144	$	—	$	5,574	$	—	$	5,574
Other liabilities	$	14,678	$	—	$	2,189	$	11,958	$	14,147
Separate account liabilities	$	82,015	$	—	$	82,015	$	—	$	82,015


	December 31, 2025
			Fair Value Hierarchy
	Carrying Value		Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Mortgage loans	$	84,593	$	—	$	—	$	82,933	$	82,933
Policy loans	$	8,547	$	—	$	—	$	9,083	$	9,083

Other invested assets	$	895	$	—	$	700	$	195	$	895
Premiums, reinsurance and other receivables	$	8,681	$	—	$	1,252	$	6,835	$	8,087
Other assets	$	247	$	—	$	53	$	202	$	255
Liabilities
PABs	$	147,826	$	—	$	—	$	145,695	$	145,695
Long-term debt	$	14,461	$	—	$	14,143	$	—	$	14,143
Collateral financing arrangement	$	352	$	—	$	—	$	322	$	322
Subordinated debt securities	$	4,155	$	—	$	4,707	$	—	$	4,707
Other liabilities	$	11,993	$	—	$	842	$	10,747	$	11,589
Separate account liabilities	$	80,164	$	—	$	80,164	$	—	$	80,164

12. Subordinated Debt Securities

Subordinated Debt Issuance

In February 2026, MetLife, Inc. issued $1.0 billion of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due March 2056 (the “5.850% Subordinated Debt”), interest on which is payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $12 million of related costs which will be amortized over the term of the debentures. The 5.850% Subordinated Debt ranks senior to MetLife, Inc.’s junior subordinated debt securities, subordinate to its senior notes and equal to its 6.350% Fixed-to-Fixed Reset Rate Subordinated Debentures due March 2055.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Equity

Preferred Stock

Preferred stock authorized, issued and outstanding was as follows at both June 30, 2026 and December 31, 2025:


Series	Shares Authorized	Shares Issued and Outstanding
Floating Rate Non-Cumulative Preferred Stock, Series A	27,600,000	24,000,000
5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D	500,000	500,000
5.625% Non-Cumulative Preferred Stock, Series E	32,200	32,200
4.75% Non-Cumulative Preferred Stock, Series F	40,000	40,000
Series A Junior Participating Preferred Stock	10,000,000	—
Not designated	161,827,800	—
Total	200,000,000	24,572,200

The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows:


		Three Months Ended June 30,									Six Months Ended June 30,
		2026				2025					2026				2025
Series		Per Share		Aggregate		Per Share		Aggregate			Per Share		Aggregate		Per Share		Aggregate
	(In millions, except per share data)									(In millions, except per share data)
A		$	0.312	$	7	$	0.351	$	8		$	0.627	$	14	$	0.706	$	17
D		$	—	—		$	—	—			$	29.375	15		$	29.375	15
E		$	351.563	12		$	351.563	11			$	703.126	23		$	703.126	22
F		$	296.875	12		$	296.875	12			$	593.750	24		$	593.750	24
G (1)		$	—	—		$	—	—			$	—	—		$	19.250	19
Total				$	31			$	31				$	76			$	97

(1)Dividends were paid through the dividend payment date of September 15, 2025, when all outstanding shares of MetLife, Inc.’s 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, were redeemed.

Common Stock

MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows:


Announcement Date	Authorization Amount		Authorization Remaining at June 30, 2026 (1)
	(In millions)
April 30, 2025	$	3,000	$	622
May 1, 2024	$	3,000	$	—

(1)The Inflation Reduction Act, signed into law on August 16, 2022, imposes a one percent excise tax, net of any allowable offsets, on certain corporate stock buybacks made after December 31, 2022. The authorization remaining at June 30, 2026 does not reflect the applicable excise tax payable.

Under these authorizations, MetLife, Inc. may purchase its common stock from the MetLife Policyholder Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934), and in privately negotiated transactions. Common stock repurchases are subject to the discretion of MetLife, Inc.’s Board of Directors and will depend upon the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value, applicable regulatory approvals, and other legal and accounting factors.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Equity (continued)

For the six months ended June 30, 2026 and 2025, MetLife, Inc. repurchased 18,790,334 shares and 23,515,546 shares of its common stock, respectively, through open market purchases for $1.5 billion and $1.9 billion, respectively, excluding applicable excise tax. The excise tax is reflected in treasury stock as part of the cost basis of the common stock repurchased.

See Note 20 for information on a common stock repurchase authorization subsequent to June 30, 2026.

Stock-Based Compensation Plans

Performance Shares and Performance Units

The MetLife, Inc. 2015 Stock and Incentive Compensation Plan (the “2015 Stock Plan”) expired on January 1, 2025. Although no further awards will be granted under this plan, all awards outstanding on the expiration date will continue until settlement, forfeiture or cancellation. Beginning January 1, 2025, MetLife, Inc. grants awards under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan (successor to the 2015 Stock Plan).

Performance Shares and Performance Units granted in 2023 were among the outstanding awards on the expiration date of the 2015 Stock Plan, which were settled in the first quarter of 2026. Performance Shares are paid in shares of MetLife, Inc.’s common stock. Performance Units are payable in cash equal to the closing price of MetLife, Inc.’s common stock on the date the Board of Directors approves the performance factor. The performance factor for the January 1, 2023 – December 31, 2025 performance period was 57.50%, which was determined within a possible range from 0% to 175%. This factor has been applied to the 906,696 Performance Shares and 107,041 Performance Units associated with the performance period that ended on December 31, 2025. As a result, in the first quarter of 2026, MetLife, Inc. issued 521,350 shares of its common stock (less withholding for taxes and other items, as applicable), excluding shares that payees choose to defer, and MetLife, Inc. or its affiliates paid the cash value of 61,549 Performance Units (less withholding for taxes and other items, as applicable).

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Equity (continued)

AOCI

Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows:


	Three Months Ended June 30, 2026
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Deferred Gains (Losses) on Derivatives		FPBs Discount Rate Remeasurement Gains (Losses)		MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses)		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	(19,380)	$	(1,015)	$	9,001	$	(56)	$	(6,403)	$	(1,374)	$	(19,227)
OCI before reclassifications	626		(518)		281		(30)		37		(1)		395
Deferred income tax benefit (expense)	(48)		109		(218)		6		(2)		—		(153)
AOCI before reclassifications, net of income tax	(18,802)		(1,424)		9,064		(80)		(6,368)		(1,375)		(18,985)
Amounts reclassified from AOCI	161		131		—		—		—		22		314
Deferred income tax benefit (expense)	(36)		(32)		—		—		—		(4)		(72)
Amounts reclassified from AOCI, net of income tax	125		99		—		—		—		18		242




Balance, end of period	$	(18,677)	$	(1,325)	$	9,064	$	(80)	$	(6,368)	$	(1,357)	$	(18,743)

	Three Months Ended June 30, 2025
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Deferred Gains (Losses) on Derivatives		FPBs Discount Rate Remeasurement Gains (Losses)		MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses)		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	(17,329)	$	179	$	5,334	$	(31)	$	(6,985)	$	(1,416)	$	(20,248)
OCI before reclassifications	908		(1,028)		884		(42)		640		(9)		1,353
Deferred income tax benefit (expense)	(142)		256		(342)		9		31		2		(186)
AOCI before reclassifications, net of income tax	(16,563)		(593)		5,876		(64)		(6,314)		(1,423)		(19,081)
Amounts reclassified from AOCI	100		(1,102)		—		—		—		22		(980)
Deferred income tax benefit (expense)	(21)		229		—		—		—		(6)		202
Amounts reclassified from AOCI, net of income tax	79		(873)		—		—		—		16		(778)

Balance, end of period	$	(16,484)	$	(1,466)	$	5,876	$	(64)	$	(6,314)	$	(1,407)	$	(19,859)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Equity (continued)


	Six Months Ended June 30, 2026
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Deferred Gains (Losses) on Derivatives		FPBs Discount Rate Remeasurement Gains (Losses)		MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses)		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	(15,614)	$	(1,588)	$	6,871	$	(97)	$	(6,263)	$	(1,393)	$	(18,084)
OCI before reclassifications	(4,472)		(19)		3,003		22		(80)		(1)		(1,547)
Deferred income tax benefit (expense)	1,116		(10)		(810)		(5)		(25)		—		266
AOCI before reclassifications, net of income tax	(18,970)		(1,617)		9,064		(80)		(6,368)		(1,394)		(19,365)
Amounts reclassified from AOCI	387		377		—		—		—		46		810
Deferred income tax benefit (expense)	(94)		(85)		—		—		—		(9)		(188)
Amounts reclassified from AOCI, net of income tax	293		292		—		—		—		37		622

Balance, end of period	$	(18,677)	$	(1,325)	$	9,064	$	(80)	$	(6,368)	$	(1,357)	$	(18,743)

	Six Months Ended June 30, 2025
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Deferred Gains (Losses) on Derivatives		FPBs Discount Rate Remeasurement Gains (Losses)		MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses)		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance at December 31, 2024	$	(19,402)	$	370	$	6,529	$	(71)	$	(7,170)	$	(1,442)	$	(21,186)
Cumulative effects of change in accounting principles for equity method investees at January 1, 2025	70		—		(1,144)		—		—		—		(1,074)
OCI before reclassifications	3,112		(811)		932		9		780		(7)		4,015
Deferred income tax benefit (expense)	(530)		151		(441)		(2)		76		2		(744)
AOCI before reclassifications, net of income tax	(16,750)		(290)		5,876		(64)		(6,314)		(1,447)		(18,989)
Amounts reclassified from AOCI	341		(1,481)		—		—		—		53		(1,087)
Deferred income tax benefit (expense)	(75)		305		—		—		—		(13)		217
Amounts reclassified from AOCI, net of income tax	266		(1,176)		—		—		—		40		(870)

Balance, end of period	$	(16,484)	$	(1,466)	$	5,876	$	(64)	$	(6,314)	$	(1,407)	$	(19,859)

(1)Primarily unrealized gains (losses) on fixed maturity securities.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Equity (continued)

Information regarding amounts reclassified out of each component of AOCI was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
AOCI Components	Amounts Reclassified from AOCI								Consolidated Statements of Operations and Comprehensive Income (Loss) Locations
	(In millions)
Unrealized investment gains (losses):
Unrealized investment gains (losses)	$	(223)	$	(97)	$	(443)	$	(382)	Net investment gains (losses)
Unrealized investment gains (losses)	—		(8)		(1)		(8)		Net investment income
Unrealized investment gains (losses)	62		5		57		49		Net derivative gains (losses)
Unrealized investment gains (losses), before income tax	(161)		(100)		(387)		(341)
Income tax (expense) benefit	36		21		94		75
Unrealized investment gains (losses), net of income tax	(125)		(79)		(293)		(266)
Deferred gains (losses) on derivatives - cash flow hedges:
Interest rate derivatives	1		6		2		23		Net investment income
Interest rate derivatives	(16)		9		(15)		9		Net investment gains (losses)

Foreign currency exchange rate derivatives	—		1		1		3		Net investment income
Foreign currency exchange rate derivatives	(116)		1,086		(365)		1,446		Net investment gains (losses)



Gains (losses) on cash flow hedges, before income tax	(131)		1,102		(377)		1,481
Income tax (expense) benefit	32		(229)		85		(305)
Gains (losses) on cash flow hedges, net of income tax	(99)		873		(292)		1,176
Defined benefit plans adjustment: (1)
Amortization of net actuarial gains (losses)	(24)		(25)		(51)		(59)
Amortization of prior service (costs) credit	2		3		5		6
Amortization of defined benefit plan items, before income tax	(22)		(22)		(46)		(53)
Income tax (expense) benefit	4		6		9		13
Amortization of defined benefit plan items, net of income tax	(18)		(16)		(37)		(40)
Total reclassifications, net of income tax	$	(242)	$	778	$	(622)	$	870

(1)These AOCI components are included in the computation of net periodic benefit costs. See Note 15.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

14. Other Revenues and Other Expenses

Other Revenues

Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
	(In millions)
Vision fee for service arrangements	$	144	$	133	$	303	$	287
Prepaid legal plans	176		158		352		319
Institutional Client asset management fees (1)	186		95		372		172
Administrative services-only contracts	82		73		163		147
Recordkeeping and administrative services (2)	35		34		69		70
Other revenue related to service contracts from customers (1) (3)	101		111		199		220
Total revenues related to service contracts from customers	724		604		1,458		1,215
Other	121		75		239		151
Total other revenues	$	845	$	679	$	1,697	$	1,366

(1)As a result of the Strategic Reorganization, the presentation of the components of other revenues was revised to report MIM segment Institutional Client asset management fees herein and, as a result, $24 million and $49 million of revenue for the three months and six months ended June 30, 2025, respectively, were reclassified to other revenue related to service contracts from customers.

(2)Related to products and businesses no longer actively marketed by the Company.

(3)Includes $11 million and $22 million for the three months and six months ended June 30, 2026, respectively, and $12 million and $24 million for the three months and six months ended June 30, 2025, respectively, for asset management fees from management of general account equity method investments. See Note 19 for additional related party transactions.

Receivables for revenues related to service contracts from customers were $370 million and $272 million at June 30, 2026 and December 31, 2025, respectively.

Other Expenses

Information on other expenses was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
	(In millions)
Amortization of DAC, VOBA and negative VOBA	$	588	$	528	$	1,156	$	1,047
Interest expense on debt	292		269		557		527
Direct:
Employee-related costs (1)	1,070		936		2,179		1,927
Third-party staffing costs	393		413		780		789
General and administrative expenses	154		130		286		256
Commissions and other variable expenses	2,033		1,606		4,060		3,153
Capitalization of DAC	(950)		(787)		(1,909)		(1,485)
Premium taxes, other taxes, and licenses & fees	194		158		393		319
Pension, postretirement and postemployment benefit costs	70		66		140		136
Total other expenses	$	3,844	$	3,319	$	7,642	$	6,669

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

14. Other Revenues and Other Expenses (continued)

(1)Includes ($52) million and ($72) million for the three months and six months ended June 30, 2026, respectively, and ($58) million and ($81) million for the three months and six months ended June 30, 2025, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

15. Employee Benefit Plans

Pension and Other Postretirement Benefit Plans

Certain subsidiaries of MetLife, Inc. sponsor a U.S. qualified and various U.S. and non-U.S. nonqualified defined benefit pension plans covering employees who meet specified eligibility requirements. These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. and non-U.S. retired employees.

The components of net periodic benefit costs, reported in other expenses, were as follows:


	Three Months Ended June 30,
	2026				2025
	Pension Benefits		Other Postretirement Benefits		Pension Benefits		Other Postretirement Benefits
	(In millions)
Service costs	$	38	$	2	$	38	$	1
Interest costs	119		12		119		10
Expected return on plan assets	(112)		(8)		(111)		(7)
Amortization of net actuarial (gains) losses	39		(11)		42		(15)
Amortization of prior service costs (credit)	(2)		—		(3)		—
Net periodic benefit costs (credit)	$	82	$	(5)	$	85	$	(11)

	Six Months Ended June 30,
	2026				2025
	Pension Benefits		Other Postretirement Benefits		Pension Benefits		Other Postretirement Benefits
	(In millions)
Service costs	$	75	$	2	$	75	$	2
Interest costs	237		23		238		21
Expected return on plan assets	(225)		(15)		(221)		(21)
Amortization of net actuarial (gains) losses	77		(22)		84		(23)
Amortization of prior service costs (credit)	(4)		(1)		(6)		—
Net periodic benefit costs (credit)	$	160	$	(13)	$	170	$	(21)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

16. Income Tax

For the three months and six months ended June 30, 2026, the effective tax rate on income (loss) before provision for income tax was 25% and 24%, respectively. The Company’s effective tax rate for the three months ended June 30, 2026 differed from the U.S. statutory rate of 21% primarily due to tax charges from (i) U.S. state and local taxes; (ii) the pending disposition of MetLife Ukraine; and (iii) non-deductible losses, partially offset by tax benefits from (i) non-taxable investment income; and (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments. The Company’s effective tax rate for the six months ended June 30, 2026 differed from the U.S. statutory rate of 21% primarily due to tax charges from (i) foreign earnings taxed at higher statutory rates than the U.S. statutory rate and foreign losses taxed at lower statutory rates; (ii) U.S. state and local taxes; (iii) the pending disposition of MetLife Ukraine; and (iv) non-deductible losses, partially offset by tax benefits from (i) non-taxable investment income; and (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments.

For the three months and six months ended June 30, 2025, the effective tax rate on income (loss) before provision for income tax was 25% and 28%, respectively. The Company’s effective tax rate for the three months ended June 30, 2025 differed from the U.S. statutory rate of 21% primarily due to tax charges from foreign earnings taxed at higher statutory rates than the U.S. statutory rate and foreign losses taxed at lower statutory rates, partially offset by tax benefits from (i) non-taxable investment income; (ii) a tax rate change in Japan; (iii) the reversal of previously non-deductible losses; and (iv) low income housing and other tax credits, partially offset by the impact of tax equity investments. The Company’s effective tax rate for the six months ended June 30, 2025 differed from the U.S. statutory rate of 21% primarily due to tax charges from (i) foreign earnings taxed at higher statutory rates than the U.S. statutory rate and foreign losses taxed at lower statutory rates; and (ii) non-deductible losses, partially offset by tax benefits from (i) non-taxable investment income; (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments; and (iii) the corporate tax deduction for stock compensation.

17. Earnings Per Common Share

The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
	(In millions, except per share data)
Weighted Average Shares:
Weighted average common stock outstanding - basic	642.6		670.8		647.3		676.5
Incremental common shares from assumed exercise or issuance of stock-based awards	4.3		4.2		4.0		4.5
Weighted average common stock outstanding - diluted	646.9		675.0		651.3		681.0
Net Income (Loss):
Net income (loss)	$	779	$	735	$	1,941	$	1,685
Less: Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests	43		6		20		11
Less: Preferred stock dividends	31		31		76		97

Net income (loss) available to MetLife, Inc.’s common shareholders	$	705	$	698	$	1,845	$	1,577
Basic	$	1.10	$	1.04	$	2.85	$	2.33
Diluted	$	1.09	$	1.03	$	2.83	$	2.32

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

18. Contingencies, Commitments and Guarantees

Contingencies

Litigation

The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lender, employer, investor, investment advisor, broker-dealer, and taxpayer.

The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the U.S. where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries.

It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established, there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at June 30, 2026. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.

Matters as to Which an Estimate Can Be Made

For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of June 30, 2026, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million.

Matters as to Which an Estimate Cannot Be Made

For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

18. Contingencies, Commitments and Guarantees (continued)

Asbestos-Related Claims

Metropolitan Life Insurance Company (“MLIC”) is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. MLIC has never engaged in the business of manufacturing or selling asbestos-containing products, nor has MLIC issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of MLIC’s employees during the period from the 1920s through approximately the 1950s and allege that MLIC learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. MLIC believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against MLIC.

MLIC’s defenses include that: (i) MLIC owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of MLIC; (iii) MLIC’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against MLIC, while other trial courts have denied MLIC’s motions. There can be no assurance that MLIC will receive favorable decisions on motions in the future. While most cases brought to date have settled, MLIC intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials.

As reported in the 2025 Annual Report, MLIC received approximately 2,782 asbestos-related claims in 2025. For the six months ended June 30, 2026 and 2025, MLIC received approximately 1,352 and 1,337 new asbestos-related claims, respectively. See Note 24 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for historical information concerning asbestos claims and MLIC’s update to its recorded liability at December 31, 2025. The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.

The ability of MLIC to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against MLIC when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts.

The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position.

The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. MLIC’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis.

MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the U.S., assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its liability analysis for asbestos-related claims through June 30, 2026.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

18. Contingencies, Commitments and Guarantees (continued)

Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017)

Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., MLIC, and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. In December 2020, the Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and MLIC’s motion to dismiss and remanded the case. The Relator filed a Fourth Amended Complaint in January 2023. On October 13, 2024, the trial court denied the defendants’ motion to dismiss the complaint. The Company intends to defend the action vigorously.

Commitments

Mortgage Loan Commitments

The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $2.4 billion at both June 30, 2026 and December 31, 2025.

Commitments to Fund Partnership Investments, Bank Credit Facilities and Private Corporate Bond Investments

The Company commits to fund partnership investments and to lend funds under bank credit facilities and private corporate bond investments. The amounts of these unfunded commitments were $11.8 billion and $11.1 billion at June 30, 2026 and December 31, 2025, respectively.

Guarantees

In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $329 million, with a cumulative maximum of $628 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees.

In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future.

The Company also has minimum fund yield requirements on certain pension funds. Since these guarantees are not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future.

The Company’s recorded liabilities were $19 million at both June 30, 2026 and December 31, 2025 for indemnities and guarantees.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

19. Related Party Transactions

In 2025, the Company invested in Chariot Holding Company, LP (“Chariot”), a Bermuda registered exempted limited partnership. The Company had unfunded contingent capital commitments to Chariot of $67 million and $94 million at June 30, 2026 and December 31, 2025, respectively. The Company accounts for its investment in Chariot under the equity method of accounting.

The Company has entered into reinsurance agreements with Chariot Re, a subsidiary of Chariot, and recorded premiums, reinsurance and other receivables of $10.9 billion and $9.8 billion and a funds withheld liability of $11.1 billion and $10.5 billion within other liabilities at June 30, 2026 and December 31, 2025, respectively. For the three and six months ended June 30, 2026, the Company also recorded net derivative gains (losses) of ($41) million and $66 million, respectively, other revenues of $34 million and $73 million, respectively, policyholder benefits and claims of ($82) million and ($156) million, respectively, and other expenses of $90 million and $182 million, respectively.

In addition, MetLife Investment Management, LLC has entered into investment management and advisory agreements with Chariot Re to manage a portion of Chariot Re’s assets. The Company recognized asset management fees from Chariot Re of $6 million and $12 million for the three months and six months ended June 30, 2026, respectively.

20. Subsequent Events

Common Stock Repurchase Authorization

On August 5, 2026, MetLife, Inc. announced that its Board of Directors authorized an additional $3.0 billion of common stock repurchases.

Table of Contents

Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations